

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018479 A1

(51) International Patent Classification⁷: **C07D 495/04**,
A61K 31/40, A61P 35/00 // (C07D 495/04, 333:00,
209:00)

(74) Agent: **ASTRAZENECA**; Global Intellectual Property,
Mereside, Alderley Park, Macclesfield, Cheshire SK10
4TG (GB).

(21) International Application Number:
PCT/GB2003/003603

(22) International Filing Date: 18 August 2003 (18.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02292076.3 21 August 2002 (21.08.2002) EP

(71) Applicant (for all designated States except MG, US): **AS-
TRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIM-
ITED** [GB/GB]; 15 Stanhope Gate, London, Greater Lon-
don W1K 1LN (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **ARNOULD, Jean,
Claude** [FR/FR]; AstraZeneca R & D Reims, Z.I. la
Pompelle, BP 1050, Cedex 2, F-51689 Reims (FR).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: THIENO-PYRROLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE



(I)

(57) Abstract: The invention relates to a group of novel thieno-pyrrole compounds of Formula (I), wherein: R¹, R², R⁴, R⁵, R⁶, R^{6a}, R⁷, R⁸, A and B are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.

THIENO-PYRROLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE

The present invention relates to compounds which are antagonists of gonadotropin releasing hormone (GnRH) activity. The invention also relates to pharmaceutical formulations, the use of a compound of the present invention in the manufacture of a medicament, a method of therapeutic treatment using such a compound and processes for producing the compounds.

Gonadotropin releasing hormone (GnRH) is a decapeptide that is secreted by the hypothalamus into the hypophyseal portal circulation in response to neural and/or chemical stimuli, causing the biosynthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the pituitary. GnRH is also known by other names, including gonadoliberin, LH releasing hormone (LHRH), FSH releasing hormone (FSH RH) and LH/FSH releasing factor (LH/FSH RF).


GnRH plays an important role in regulating the action of LH and FSH (by regulation of their levels), and thus has a role in regulating the levels of gonadal steroids in both sexes, including the sex hormones progesterone, oestrogens and androgens. More discussion of GnRH can be found in WO 98/5519 and WO 97/14697, the disclosures of which are incorporated herein by reference.

It is believed that several diseases would benefit from the regulation of GnRH activity, in particular by antagonising such activity. These include sex hormone related conditions such as sex hormone dependent cancer, benign prostatic hypertrophy and myoma of the uterus. Examples of sex hormone dependent cancers are prostatic cancer, uterine cancer, breast cancer and pituitary gonadotrophe adenoma.

The following disclose compounds purported to act as GnRH antagonists:
WO 97/21435, WO 97/21703, WO 97/21704, WO 97/21707, WO 55116, WO 98/55119, WO 98/55123, WO 98/55470, WO 98/55479, WO 99/21553, WO 99/21557, WO 99/41251, WO 99/41252, WO 00/04013, WO 00/69433, WO 99/51231, WO 99/51232, WO 99/51233, WO 99/51234, WO 99/51595, WO 99/51596, WO 00/53178, WO 00/53180, WO 00/53179, WO 00/53181, WO 00/53185, WO 00/53602, WO 02/066477, WO 02/066478, WO 02/06645 and WO 02/092565.

It would be desirable to provide further compounds, such compounds being GnRH antagonists. Thus, according to the first aspect of the invention there is provided a compound of Formula (I),

- 2 -




Formula (I)

wherein

A represents a direct bond or optionally substituted C₁₋₅alkylene;

5 **B** is a group of Formula (II):



Formula (II);

wherein at position (a) Formula (II) is attached to the nitrogen atom and the group **X** is attached to **R⁸**;

10 **R¹** represents hydrogen; optionally substituted C₁₋₈alkyl; or (CH₂)_b-**R^a**, wherein

R^a represents C₃₋₈cycloalkyl and **b** is zero or an integer from 1 to 6;


R² represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR³R^{3a}, optionally substituted C₁₋₈alkyl, optionally substituted C₁₋₈alkoxy or halo;

15 **R³** and **R^{3a}** are independently selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;

R⁴ is hydrogen;

R⁵ is selected from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group
20 of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**, **III-g**, **III-h**, **III-i**, **III-j**, **III-k** or **III-l**;

- 3 -




wherein **het** represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R⁶ and **R**^{6a}, are independently selected from hydrogen and optionally substituted C₁₋₈alkyl;

5 or **R**⁶ and **R**^{6a} together represent carbonyl;

R⁷ represents hydrogen or optionally substituted C₁₋₈alkyl;

or **R**⁶  **A-N-R**⁷ together form an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and **R**^{6a} represents hydrogen and optionally substituted C₁₋₈alkyl;

10 **X** and **R**⁸ are selected from:

(i) **X** represents N and **R**⁸ is selected from:

cyano, hydrogen, hydroxy, -O-**R**^b, -C(O)-**R**^b, -N**R**^b**R**^c -C(O)O-**R**^b, -CON**R**^b**R**^c or NH-C(O)-**R**^b, where **R**^b and **R**^c are independently selected from hydrogen and C₁₋₄alkyl optionally substituted with hydroxy, amino, N-C₁₋₄alkylamino, N,N-di-C₁₋₄alkylamino, HO-C₂₋₄alkyl-NH- or HO-C₂₋₄alkyl-N(C₁₋₄alkyl)-;

(ii) **X** represents CH and **R**⁸ represents NO₂; and

(iii) =**X-R**⁸ together represent =O;

R¹¹ is a group of the formula: N(**R**⁹**R**¹⁰) wherein **R**⁹ represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or

20 optionally-substituted C₁₋₈alkyl and **R**¹⁰ represents hydrogen or optionally substituted

- 4 -


C₁₋₈alkyl; or

the structure N(R⁹R¹⁰) represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

- 5 R¹² and R^{12a} are independently selected from hydrogen or optionally substituted C₁₋₈alkyl; or R¹² and R^{12a} together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

R¹³ and R¹⁴ are selected from:


- 10 (i) R¹³ is selected from hydrogen; optionally substituted C₁₋₈alkyl; optionally substituted aryl; -R^d-Ar, where R^d represents C₁₋₈alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and R¹⁴ is selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;
- 15 (ii) where R⁵ represents a group of formula **III-a**, **III-b**, **III-i** or **III-k**, then the group NR¹³(-R¹⁴) represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

- 20 (iii) where R⁵ represents structure **III-e**, then the group  represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

R¹⁷ is selected from: hydrogen and C₁₋₄alkyl;

or a salt, pro-drug or solvate thereof.

25 According to a further feature of the first aspect of the invention there is provided a compound of Formula (Ia),




Formula (Ia)

- 5 -

wherein

A represents a direct bond or optionally substituted C₁₋₅alkylene;

B is a group of Formula (II):



5

Formula (II);

wherein at position (a) Formula (II) is attached to the nitrogen atom and the group **X** is attached to **R**⁸;

R¹ represents hydrogen; optionally substituted C₁₋₈alkyl; or (CH₂)_b-**R**^a, wherein


R^a represents C₃₋₈cycloalkyl and **b** is zero or an integer from 1 to 6;

10 **R**² represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR³R^{3a}, optionally substituted C₁₋₈alkyl, optionally substituted C₁₋₈alkoxy or halo;

R³ and **R**^{3a} are independently selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;

15 **R**⁴ is hydrogen;

R⁵ is selected from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula **III-a**; **III-b**; **III-c**; **III-d**; **III-e**; **III-f**, **III-g**, **III-h**, **III-i** or **III-j**;



wherein **het** represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R^6 and R^{6a} , are independently selected from hydrogen and optionally substituted C_{1-8} alkyl;
 5 or R^6 and R^{6a} together represent carbonyl;

R^7 represents hydrogen or optionally substituted C_{1-8} alkyl;

or R^6 --- A-N-R^7 together form an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S,
 and R^{6a} represents hydrogen and optionally substituted C_{1-8} alkyl;

10 **X** and R^8 are selected from:

(i) **X** represents N and R^8 is selected from:

cyano, hydrogen, hydroxy, $-\text{O-R}^b$, $-\text{NR}^b\text{R}^c$, $-\text{C(O)O-R}^b$, $-\text{CONR}^b\text{R}^c$ or NH-C(O)-R^b , where R^b and R^c are independently selected from hydrogen and C_{1-4} alkyl optionally substituted with hydroxy, amino, N- C_{1-4} alkylamino,
 15 N,N-di- C_{1-4} alkylamino, HO- C_{2-4} alkyl-NH- or HO- C_{2-4} alkyl-N(C_{1-4} alkyl)-;

(ii) **X** represents CH and R^8 represents NO_2 ; and

(iii) **X**- R^8 together represent $-\text{O}-$;

R^{11} is a group of the formula: $\text{N(R}^9\text{R}^{10})$ wherein R^9 represents hydrogen, aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted


- 7 -

C₁₋₈alkyl and **R**¹⁰ represents hydrogen or optionally substituted C₁₋₈alkyl; or the structure N(**R**^{9**R**¹⁰) represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;}

- 5 **R**¹² and **R**^{12a} are independently selected from hydrogen or optionally substituted C₁₋₈alkyl; or **R**¹² and **R**^{12a} together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

R¹³ and **R**¹⁴ are selected from:

- 10 (i) **R**¹³ is selected from hydrogen; optionally substituted C₁₋₈alkyl; optionally substituted aryl; -**R**^d-Ar, where **R**^d represents C₁₋₈alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and **R**¹⁴ is selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;
- 15 (ii) where **R**⁵ represents a group of formula **III-a**, **III-b** or **III-i**, then the group **NR**¹³(-**R**¹⁴) represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

- 20 (iii) where **R**⁵ represents structure **III-e**, then the group  represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

or a salt, pro-drug or solvate thereof.

According to a further feature of the first aspect of the invention there is provided a pharmaceutical formulation comprising a compound of Formula (I) or Formula (Ia), or salt, 25 pro-drug or solvate thereof, and a pharmaceutically acceptable diluent or carrier.

According to a further feature of the first aspect of the invention there is provided the following uses of a compound of a compound of Formula (I) or Formula (Ia), or salt, pro-drug or solvate thereof:

- 30 (a) the use in the manufacture of a medicament for antagonising gonadotropin releasing hormone activity;
- (b) the use in the manufacture of a medicament for administration to a patient, for reducing the secretion of luteinizing hormone by the pituitary gland of the patient; and

- 8 -

- (c) the use in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient, preferably a sex hormone related condition selected from prostate cancer and pre-menopausal breast cancer.

5 According to a further aspect of the invention there is provided a method of antagonising gonadotropin releasing hormone activity in a patient, comprising administering a compound of Formula (I) or Formula (Ia), or salt, pro-drug or solvate thereof, to a patient.

Whilst pharmaceutically-acceptable salts of compounds of the invention are preferred, other non-pharmaceutically-acceptable salts of compounds of the invention may also be
10 useful, for example in the preparation of pharmaceutically-acceptable salts of compounds of the invention.

Whilst the invention comprises compounds of the invention, and salts, pro-drugs or solvates thereof, in a further embodiment of the invention, the invention comprises compounds of the invention and salts thereof.

15 In the present specification, unless otherwise indicated, an **alkyl**, **alkylene** or **alkenyl** moiety may be linear or branched.

The term "**alkylene**" refers to the group $-\text{CH}_2-$. Thus, C_8 alkylene for example is $-(\text{CH}_2)_8-$.

The term "**aryl**" refers to phenyl or naphthyl.

20 The term "**carbamoyl**" refers to the group $-\text{CONH}_2$.

The term "**halo**" refers to fluoro, chloro, bromo or iodo.


The term "**heterocyclyl**" or "**heterocyclic ring**" refers to a 4-12 membered, preferably 5-10 membered aromatic mono or bicyclic ring or a 4-12 membered, preferably 5-10 membered saturated or partially saturated mono or bicyclic ring, said aromatic, saturated or
25 partially unsaturated rings containing up to 5 heteroatoms independently selected from nitrogen, oxygen or sulphur, linked via ring carbon atoms or ring nitrogen atoms where a bond from a nitrogen is allowed, for example no bond is possible to the nitrogen of a pyridine ring, but a bond is possible through the 1-nitrogen of a pyrazole ring. Examples of 5- or 6-membered aromatic heterocyclic rings include pyrrolyl, furanyl, imidazolyl, triazolyl,
30 pyrazinyl, pyrimidinyl, pyridazinyl, pyridinyl, isoxazolyl, oxazolyl, 1,2,4 oxadiazolyl, isothiazolyl, thiazolyl and thienyl. A 9 or 10 membered bicyclic aromatic heterocyclic ring is an aromatic bicyclic ring system comprising a 6-membered ring fused to either a 5 membered ring or another 6 membered ring. Examples of 5/6 and 6/6 bicyclic ring systems include


- 9 -

benzofuranyl, benzimidazolyl, benzthiophenyl, benzthiazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, indolyl, pyridoimidazolyl, pyrimidoimidazolyl, quinoliny, isoquinoliny, quinoxaliny, quinazoliny, phthalaziny, cinnoliny and naphthyridiny. Examples of saturated or partially saturated heterocyclic rings include pyrroliny, pyrrolidinyl, morpholiny, piperidinyl, piperaziny, dihydropyridiny and dihydropyrimidinyl. . This definition further comprises sulphur-containing rings wherein the sulphur atom has been oxidised to an S(O) or S(O₂) group.

The term "**aromatic ring**" refers to a 5-10 membered aromatic mono or bicyclic ring optionally containing up to 5 heteroatoms independently selected from nitrogen, oxygen or sulphur. Examples of such "aromatic rings" include: phenyl, pyrrolyl, furanyl, imidazolyl, triazolyl, pyraziny, pyrimidinyl, pyridaziny, pyridiny, isoxazolyl, oxazolyl, 1,2,4 oxadiazolyl, isothiazolyl, thiazolyl and thienyl. Preferred aromatic rings include 'phenyl, thienyl and pyridyl.

The symbol  denotes where the respective group is linked to the remainder of the molecule.

For the avoidance of doubt, when R^6  together form an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, then the groups shown cyclise to form a nitrogen-containing heterocyclic ring, i.e



, optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.

Examples of **C₁₋₈alkyl** include: methyl, ethyl, propyl, isopropyl, butyl, *iso*-butyl, *tert*-butyl and 2-methyl-pentyl; example of **C₁₋₈alkylene** include: methylene, ethylene and 2-methyl-propylene; examples of **C₁₋₈alkoxy** include methoxy, ethoxy and butyloxy; examples of **N-C₁₋₄alkylamino** include N-methylamino and N-ethylamino; examples of **N,N-di-C₁₋₄alkylamino**, examples of **HO-C₂₋₄alkyl-NH** include hydroxymethylamino hydroxyethylamino and hydroxypropylamino, examples of **HO-C₂₋₄alkyl-N(C₁₋₄alkyl)** include

- 10 -

N-methyl-hydroxymethylamino, N-ethyl-hydroxyethylamino, and N-propyl-hydroxypropylamino.

It is to be understood that, insofar as certain of the compounds of the invention may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, 5 the invention includes in its definition any such optically active or racemic form which possesses the property of antagonizing gonadotropin releasing hormone (GnRH) activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, activity of these compounds may be 10 evaluated using the standard laboratory techniques referred to hereinafter.

The invention also relates to any and all tautomeric forms of the compounds of the different features of the invention that possess the property of antagonizing gonadotropin releasing hormone (GnRH) activity.

It will also be understood that certain compounds of the present invention may exist in 15 solvated, for example hydrated, as well as unsolvated forms. It is to be understood that the present invention encompasses all such solvated forms which possess the property of antagonizing gonadotropin releasing hormone (GnRH) activity.

Preferred compounds of Formula (I) are those wherein any one of the following or a combination of the following apply.


20 Preferably **A** represents optionally substituted C₁₋₅alkylene. Further preferably C₁₋₄alkylene. Most preferably methylene or ethylene.

Preferably **R**¹ represents hydrogen or optionally substituted C₁₋₆alkyl. More preferably **R**¹ represents hydrogen or unsubstituted C₁₋₆alkyl. Yet more preferably **R**¹ represents hydrogen, methyl, ethyl or *tert*-butyl. Most preferably **R**¹ represents hydrogen.

25 Preferably **R**² represents an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, **NR**^e**R**^f, optionally substituted C₁₋₈alkyl (preferably, C₁₋₄alkyl, eg, methyl or ethyl), optionally substituted C₁₋₈alkoxy (preferably, C₁₋₆alkoxy, eg, methoxy, ethoxy or *tert*-butoxy) or halo (eg, F, Br or Cl) wherein **R**^e and **R**^f are independently selected from hydrogen, C₁₋₆alkyl or aryl. Further preferably **R**² 30 is optionally substituted phenyl wherein the optional substituents are selected from cyano, **NR**^e**R**^f, optionally substituted C₁₋₄alkyl, optionally substituted C₁₋₆alkoxy, F, Br or Cl wherein **R**^e and **R**^f are as defined above. Yet further preferably **R**² is optionally substituted phenyl wherein the optional substituents are selected from methyl, ethyl, methoxy, ethoxy,

- 11 -


tert-butoxy, F or Cl. Most preferably R^2 represents




wherein Me represents methyl. Preferably R^2 bears 1, 2 or 3 substituents.

Preferably R^3 and R^{3a} are independently selected from hydrogen; optionally substituted C_{1-6} alkyl and , optionally substituted aryl . Further preferably R^3 and R^{3a} are independently selected from methyl, ethyl, *tert*-butyl and phenyl.

Preferably R^5 is selected from a group of formula **III-a** , **III-g**, **III-h**, **III-i** or **III-j**:




Further preferably R^5 is selected from one of the following groups:




- 12 -

Yet further preferably R^5 is selected from one of the following groups:




wherein Me represents methyl.

Yet further preferably R^5 is selected from one of the following groups:



5

Most preferably R^5 is:



Preferably R^6 and R^{6a} are independently selected from hydrogen, fluoro or optionally substituted C_{1-6} alkyl. Preferably R^6 and R^{6a} are independently selected from hydrogen, fluoro and unsubstituted C_{1-6} alkyl. Yet more preferably R^6 and R^{6a} are independently selected from hydrogen or methyl. Most preferably R^6 is hydrogen and R^{6a} is methyl.

In a further embodiment of the invention, R^6 and R^{6a} each represent hydrogen and A represents C_{1-4} alkylene (preferably methylene).

In a yet further embodiment of the invention R^6 represents hydrogen, R^{6a} represents methyl, and A represents C_{1-4} alkylene (preferably methylene).

Preferably R^7 is selected from hydrogen or optionally-substituted C_{1-6} alkyl. Further preferably R^7 represents hydrogen, methyl, ethyl or *tert*-butyl). Most preferably R^7 is hydrogen.

Preferably X and R^8 are selected from:-

20 (a) $=X-R^8$ represents $=O$; or

- 13 -

(b) **X** represents N and **R**⁸ represents hydrogen, hydroxy, cyano, $-\text{O}-\text{R}^b$, $-\text{C}(\text{O})-\text{R}^b$, $-\text{C}(\text{O})\text{O}-\text{R}^b$ and $-\text{C}(\text{O})\text{NR}^b\text{R}^c$; wherein **R**^b and **R**^c are as defined above.

Further preferably **X** and **R**⁸ represent either:-

(a) **X** represents N and **R**⁸ represents cyano or $-\text{C}(\text{O})\text{O}-\text{R}^b$; or

5 (b) **X** represents N and **R**⁸ represents hydrogen.

Further preferably **X** and **R**⁸ represent either:-

(a) **X** represents N and **R**⁸ represents cyano or $-\text{C}(\text{O})\text{O}-\text{R}^b$; wherein **R**^b represents C₁₋₆alkyl;

In a further embodiment of the invention **X** represents N and **R**⁸ represents $-\text{CONR}^b\text{R}^c$

10 wherein **R**^b and **R**^c are as defined above.

In a further embodiment of the invention the group $=\text{X}-\text{R}^8$ is selected from:

(a) **X** represents N and **R**⁸ represents hydrogen, cyano, hydroxy, $-\text{O}-\text{R}^b$, $-\text{C}(\text{O})-\text{R}^b$, and $-\text{C}(\text{O})\text{O}-\text{R}^b$, wherein **R**^b is selected from methyl, ethyl or isopropyl;

(b) **X** represents N and **R**⁸ represents carbamoyl; and

15 (c) $=\text{X}-\text{R}^8$ represents $=\text{O}$.

In a further embodiment of the invention the group $=\text{X}-\text{R}^8$ is selected from:

(a) **X** represents N and **R**⁸ represents hydrogen, cyano, hydroxy, carbamoyl, acetyl, methoxy, methoxycarbonyl, ethoxycarbonyl or isopropoxycarbonyl; and

(b) $=\text{X}-\text{R}^8$ represents $=\text{O}$. In a further embodiment of the invention the group $=\text{X}-\text{R}^8$ is

20 selected from:

(a) **X** represents N and **R**⁸ represents methoxycarbonyl, ethoxycarbonyl or isopropoxycarbonyl; and

(b) $=\text{X}-\text{R}^8$ represents $=\text{O}$.

Preferably **R**⁹ comprises part of the optionally substituted heterocyclic ring $\text{N}(\text{R}^9\text{R}^{10})$ or
 25 is hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C₁₋₆alkyl, preferably C₁₋₄alkyl, wherein the optional substituents are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-\text{O}-\text{R}^b$, $\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^b\text{R}^c$, $-\text{NR}^c\text{C}(\text{O})-\text{R}^b$,
 30 $-\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^c\text{S}(\text{O}_{0-2})\text{R}^b$, $-\text{S}(\text{O}_{0-2})\text{R}^b$, wherein **R**^b and **R**^c are as defined above.



Further preferably **R**⁹ comprise part of the optionally substituted heterocyclic ring $\text{N}(\text{R}^9\text{R}^{10})$ or is selected from optionally substituted C₁₋₆alkyl.

- 14 -


Yet further preferably R^9 comprise part of the optionally substituted heterocyclic ring $N(R^9R^{10})$ or is selected from optionally substituted C_{1-6} alkyl, wherein the optional substituents are selected from: cyano or an optionally substituted 3 to 10 membered heterocyclic ring.

Yet further preferably R^9 comprise part of the optionally substituted heterocyclic ring
 5 $N(R^9R^{10})$.

When R^9 is a C_{1-6} alkyl group substituted by an optionally-substituted 3 to 10 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S, the heterocyclic ring is preferably selected from pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl, benztriazolyl,
 10 benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl, 2-azetanyl, each of which is optionally substituted, wherein the optional substituents are preferably selected from R^{16} . Further preferably a group of formula VI-a, VI-b, VI-c, VI-d, VI-e, VI-f, VI-g, VI-h, VI-i, VI-j or VI-k:, wherein each group is optionally substituted by one or more groups selected from R^{16} .



Further preferably a group of formula VI-b, VI-i, or VI-j:



wherein

20 R^{16} represents hydrogen, aryl, a 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4} alkyl wherein the optional substituents are selected from: hydroxy, amino, nitro, cyano,

- 15 -


optionally-substituted phenyl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$, $-S(O_{0-2})R^b$, wherein R^b and R^c are as defined above; Preferably R^{16} represents hydrogen or C_{1-4} alkyl optionally substituted by hydroxy, amino, nitro or cyano. Most preferably R^{16} represents hydrogen or methyl.

Most preferably when R^9 is a C_{1-6} alkyl group substituted by an optionally-substituted 3 to 10 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S, the heterocyclic ring is preferably selected piperazinyl, pyridyl or pyrrolyl, optionally substituted with methyl.


When R^9 is a C_{1-6} alkyl group substituted by an optionally-substituted 3 to 10 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S, the C_{1-6} alkyl group is preferably selected from ethyl or propyl.

Preferably R^{10} comprises part of the group $N(R^9R^{10})$ or is optionally substituted C_{1-6} alkyl. Further preferably R^{10} comprises part of the group $N(R^9R^{10})$ or is selected from: methyl, ethyl or *tert*-butyl. Most preferably R^{10} comprises part of the group $N(R^9R^{10})$.


When $N(R^9R^{10})$ represent an optionally substituted 3- to 10- membered heterocyclic ring, $N(R^9R^{10})$ is preferably selected from a 5- or 6-membered monocyclic ring containing between 1 and 3 (preferably 1 or 2) heteroatom independently selected from O, N and S. Further preferably a 5- or 6-membered monocyclic ring containing between 1 and 3 (preferably 1 or 2) heteroatom independently selected from O, N and S selected from pyrrolidinyl, thienyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl piperazinyl, imidazole, or azetidiny. Further preferably the structure $N(R^9R^{10})$ is a heterocyclic ring selected from an optionally-substituted group of formula, IV-a, IV-b, IV-c, IV-d and IV-e, wherein the optional substituents are preferably selected from the groups listed for R^{15} below




IV-a




IV-b



IV-c




IV-d



IV-e

- 16 -

Further preferably the structure $N(R^9R^{10})$ is selected from a group of formula **Va**, **Vb** or **Vc**:



Most preferably the structure $N(R^9R^{10})$ is a group of formula **V-a** or **V-c**:

R^{15} represents the group R^{15a} -Z-

5 wherein:

R^{15a} represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4} alkyl, wherein the optional substituents are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4
 10 heteroatoms independently selected from O, N and S, $-O-R^g$, $-C(O)-R^g$, $-C(O)NR^gR^h$, $--NR^gR^h$, $-NR^hC(O)-R^g$, $-C(O)NR^gR^h$, $-NR^hS(O_{0-2})R^g$, $-S(O_{0-2})R^g$, wherein R^g and R^h are independently selected from: heterocyclyl, hydrogen and C_{1-4} alkyl optionally substituted with hydroxy, amino, N- C_{1-4} alkylamino, N,N-di- C_{1-4} alkylamino, HO- C_{2-4} alkyl-NH- or HO- C_{2-4} alkyl-N(C_{1-4} alkyl)-. Preferably
 15 R^{15} is heterocyclyl, $-C(O)$ -heterocyclyl or $-(CH_2)_{0-2}-C(O)NR^gR^h$, wherein R^g and R^h are independently selected from C_{1-4} alkyl or hydrogen; and

Z is selected from: a direct bond, $-(CH_2)_{s1}-$, $-(CH_2)_{s1}-O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-S(O_n)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})C(O)N(R^{18})-(CH_2)_{s2}-$,
 20 $-(CH_2)_{s1}-OC(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})C(O)O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OC(O)N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OS(O_n)-(CH_2)_{s2}-$, or $-(CH_2)_{s1}-S(O_n)-O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-S(O)_2N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})S(O)_2-(CH_2)_{s2}-$; wherein the $-(CH_2)_{s1}-$ and $-(CH_2)_{s2}-$ groups are independently optionally substituted by hydroxy or C_{1-4} alkyl and **s1** and **s2** are
 25 independently an integer from 0 to 2, wherein **s1+s2** is less than or equal to 2 and R^{18} is selected from hydrogen or C_{1-4} alkyl (preferably hydrogen).

Preferred values for **Z** are selected from: $-(CH_2)_{s1}-$, $-(CH_2)_{s1}-O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)-$, $-C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})-$, $-(CH_2)_{s1}-C(O)N(R^{18})-$,

- 17 -

$-(\text{CH}_2)_{s1}-\text{N}(\text{R}^{18})\text{C}(\text{O})-(\text{CH}_2)_{s2}-$, $-(\text{CH}_2)_{s1}-\text{S}(\text{O})_2\text{N}(\text{R}^{18})-$ or $-(\text{CH}_2)_{s1}-\text{NHS}(\text{O})_2-$,

wherein $s1$ and $s2$ are independently selected from 0, 1, or 2 and $s1+s2$ is less than or equal to 2, R^{18} is selected from hydrogen or C_{1-4} alkyl (preferably hydrogen) and the $-(\text{CH}_2)_s-$ group is optionally substituted by hydroxy or C_{1-4} alkyl.

- 5 Further preferred values for Z are selected from: a direct bond, methylene, ethylene, propylene, oxy, 2-hydroxypropylene, carbonyl, methylcarbonyl, ethylcarbonyl, (methyl)methylcarbonyl, (ethyl)methylcarbonyl, carbonylmethylene, carbonylethylene, ethoxyethylene, amino, 2-hydroxypropylamino, carbonylamino, methylcarbonylamino, aminocarbonyl, methylaminocarbonyl, methylaminocarbonylmethyl, propylsulphonylamino
10 or methylaminosulphonyl

The most preferred values for Z are a direct bond or carbonyl.

Further preferably R^{15} is selected from: N-isopropylaminocarbonylmethyl, tetrahydropyranyl, morpholinocarbonyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl or thiazolyl.

- 15 Yet further preferably R^{15} is N-isopropylaminocarbonylmethyl, tetrahydropyranyl, morpholinocarbonyl or pyridyl.

Most preferably R^{15} is pyridyl.

- In a further embodiment of the invention R^{15} represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted
20 C_{1-4} alkyl wherein the optional substituents on aryl, a heterocyclic ring or C_{1-4} alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-\text{O}-\text{R}^b$, $\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^c\text{R}^b$, $-\text{NR}^c\text{C}(\text{O})-\text{R}^b$, $-\text{C}(\text{O})\text{NR}^b\text{R}^c$, $-\text{NR}^c\text{S}(\text{O}_{0-2})\text{R}^b$, $-\text{S}(\text{O}_{0-2})\text{R}^b$, wherein R^b and R^c are as defined above. Preferably R^{15} is
25 heterocyclyl. Further preferably R^{15} is selected from: pyridyl, pyrazinyl, pyridazinyl, tetrahydropyranyl, pyrimidinyl or thiazolyl. Most preferably R^{15} is pyridyl.

In a further embodiment of the invention $\text{N}(\text{R}^9\text{R}^{10})$ represent an optionally substituted 3- to 10- membered heterocyclic ring, wherein the optional substituents are selected from R^{15} as defined above.

- 30 Preferably R^{12} and R^{12a} are independently selected from: hydrogen, optionally substituted C_{1-6} alkyl or R^{12} and R^{12a} together with carbon to which they are attached from an optionally substituted 3- to 6-membered cycloalkyl ring. Further preferably R^{12} and R^{12a} are

- 18 -

independently selected from: hydrogen, methyl, ethyl or *tert*-butyl. Most preferably R^{12} and R^{12a} are both methyl.

Preferably R^{13} and R^{14} , are independently selected from hydrogen, optionally substituted C_{1-6} alkyl, optionally substituted phenyl and $-R^d$ -phenyl, where R^d represents
 5 C_{1-6} alkylene or and an optionally substituted 3- to 8- membered heterocyclic ring (preferably, a 5- or 6-membered monocyclic ring) containing from 1 to 3 (preferably 1 or 2) further heteroatoms independently selected from O, N and S. Further preferably R^{13} and R^{14} , are independently selected from hydrogen or C_{1-6} alkyl.

Where optional substitution is mentioned at various places, this refers to one, two, three
 10 or more optional substituents. Unless otherwise indicated above (ie, where a list of optional substituents is provided), each substituent can be independently selected from C_{1-8} alkyl (eg, C_{2-6} alkyl, and most preferably methyl, ethyl or *tert*-butyl); C_{3-8} cycloalkoxy, preferably cyclopropoxy, cyclobutoxy or cyclopentoxo; C_{1-6} alkoxy, preferably methoxy or C_{2-4} alkoxy; halo, preferably Cl or F; Hal_3C- , Hal_2CH- , $HalCH_2-$, Hal_3CO- , Hal_2CHO or $Hal CH_2O$,
 15 wherein Hal represents halo (preferably F); R^gCH_2O- , $R^hC(O)N(R)-$, $R^hSO_2N(R)-$ or R^g-R^hN- , wherein R^g and R^h independently represent hydrogen or C_{1-8} alkyl (preferably methyl or C_{2-6} alkyl or C_{2-4} alkyl), or R^g-R^hN- represents an optionally substituted C_{3-8} , preferably C_{3-6} , heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; hydrogen; or $R^kC(O)O-$ or $R^kC(O)-$, R^k representing hydrogen, optionally
 20 substituted phenyl or C_{1-6} alkyl (preferably methyl, ethyl, *iso*-propyl or *tert*-butyl). For optional substitution of the heterocyclic ring represented by R^g-R^hN- , at least one (eg, one, two or three) substituents may be provided independently selected from C_{1-6} alkyl (eg, C_{2-4} alkyl, more preferably methyl); phenyl; CF_3O- ; F_2CHO- ; C_{1-8} alkoxy, preferably methoxy, ethoxy or C_{3-6} alkoxy; C_{1-8} alkoxyC(O), preferably methoxycarbonyl, ethoxycarbonyl,
 25 *tert*-butoxycarbonyl or C_{3-6} alkoxyC(O)-; phenoxycarbonyl; phenoxy; C_{1-8} alkanoyl, preferably acetyl, ethanoyl or C_{3-6} alkylthio; carboxy; C_{1-8} alkylS(O)_{nn} wherein nn is an integer between 0 and 2, preferably methylthio, ethylthio, C_{3-6} alkylthio, methylsulphinyl, ethylsulphinyl, C_{3-6} alkylsulphinyl, methylsulphonyl, ethylsulphonyl or C_{3-6} alkylsulphonyl; hydroxy; halo (eg, F, Cl or Br); R^mR^nN- where R^m and R^n are independently hydrogen or
 30 C_{1-6} alkyl (preferably C_{2-4} alkyl, more preferably methyl, most preferably $R^m=R^n$ =methyl); and nitro.

Where optional substitution of a ring is mentioned at various places, this most preferably refers to one, two, three or more substituents selected from C_{1-8} alkyl (eg, C_{2-6} alkyl,

- 19 -

and most preferably methyl); C₁₋₈alkoxy, preferably methoxy, ethoxy or C₃₋₆alkoxy; C₁₋₈alkylS(O)_{nn} wherein **nn** is an integer between 0 and 2, preferably methylthio, ethylthio, C₃₋₆alkylthio, methylsulphinyl, ethylsulphinyl, C₃₋₆alkylsulphinyl, methylsulphonyl, ethylsulphonyl or C₃₋₆alkylsulphonyl; halo (eg, F, Cl or Br); cyano; and NO₂.

- 5 A preferred group of compounds of the invention comprise compounds of Formula (I) wherein:

R¹¹ is a group of the formula: N(**R⁹R¹⁰**); and

N(**R⁹R¹⁰**) represents an optionally-substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S, preferably substituted by heterocyclcl;

10

or a salt, pro-drug or solvate thereof.

A preferred group of compounds of the invention comprise compounds of Formula (I) wherein:


R¹¹ is a group of the formula: N(**R⁹R¹⁰**);

- 15 **R⁹** is a C₁₋₆alkyl group substituted by an optionally-substituted 3 to 8 membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; and

R¹⁰ represents hydrogen or C₁₋₆alkyl

or a salt, pro-drug or solvate thereof.

- 20 A preferred group of compounds of the invention comprises a compound of Formula (Ib):




Formula (Ib)

wherein:

- 25 **A, B, X, R¹, R², R³, R^{3a}, R⁴, R⁶, R^{6a}, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹² and R^{12a}** are as defined above; or a salt, pro-drug or solvate thereof.

- 20 -


A preferred group of compounds of the invention comprises a compound of Formula (Ic):



Formula (Ic)

5 wherein:


R⁵ is selected from a **IIIa**, **IIIb**, **IIIg**, **IIIi** or **IIIj**:



and **A**, **B**, **X**, **R¹**, **R³**, **R³ᵃ**, **R⁴**, **R⁶**, **R⁶ᵃ**, **R⁷**, **R⁸**, **R⁹**, **R¹⁰**, **R¹¹**, **R¹²**, **R¹²ᵃ**, **R¹³**, and **R¹⁴** are as defined above;

10 or a salt, pro-drug or solvate thereof.


A further preferred group of compounds of the invention comprises a compound of Formula (Id):



- 21 -

Formula (Id)

wherein:


 R^5 is selected from a **IIIa**, **IIIb**, **IIIg**, **IIIi** or **IIIj**:

5 and **A**, **B**, **X**, R^1 , R^2 , R^3 , R^{3a} , R^4 , R^5 , R^6 , R^{6a} , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{12a} , R^{13} , and R^{14} are as defined above;

or a salt, pro-drug or solvate thereof.

A yet further preferred group of compounds of the invention comprises a compound of Formula (Ib), (Ic) or (Id) wherein:

10 R^5 is a group of formula **IIIa**:



$NR^{13}(-R^{14})$ represents an optionally substituted 7- to 8- membered bicyclic heterocyclic ring and **A**, **B**, **X**, R^1 , R^2 , R^3 , R^{3a} , R^4 , R^6 , R^{6a} , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} and R^{12a} are as defined above;

15 or a salt, pro-drug or solvate thereof.

Particularly preferred compounds according to the present invention are wherein the compound is selected from:

2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-

4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido)

20 ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-b]pyrrole;

- 22 -

- 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
- 2-(2-pyrrolidin-1-yl-1,1-dimethyl-2-oxoethyl)-
5 4-[1*S*-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
- 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1*S*-methyl-2-(N'-isopropoxycarbonyl-4-tetrahydropyran-4-yl-piperidin-1-ylcarboximidamido)ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
- 10 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1*S*-methyl-2-(3-pyrid-4-yl-pyrrolidin-1-ylcarbonyl)ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
- 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1*S*-methyl-2-(N'-ethoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-
15 (3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
- or a salt, pro-drug or solvate thereof.

In another embodiment of the invention particularly preferred compounds are wherein the compound is selected from:

- isopropyl (1*E*)({(2*R*)-2-[2-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylidene carbamate;
- 20 isopropyl (1*E*)-{(2- [2-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]ethyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylidene carbamate;
- 25 isopropyl (1*E*)({(2*R*)-2-[2-[2-pyrrolidin-1-yl-1,1-dimethyl-2-oxoethyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylidene carbamate;
- methyl (1*E*)({(2*R*)-2-[2-[2-pyrrolidin-1-yl-1,1-dimethyl-2-oxoethyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylidene carbamate;
- 30 yl)methylidene carbamate;
- isopropyl (1*E*)({(2*R*)-2-[2-[N,N-dimethylamino -1,1-dimethyl-2-oxoethyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylidene carbamate;

- 23 -

isopropyl (1E)((2R)-2-[2-[1,1-dimethyl-1-cyano-methyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylidinecarbamate;

isopropyl (1E)((2R)-2-[2-[ethoxycarbonyl-1,1-dimethyl-methyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylidinecarbamate;

isopropyl (1E)((2R)-2-[2-[aminocarbonyl-1,1-dimethyl-methyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylidinecarbamate; and

N-{(2R)-2-[2-(1,1-dimethyl-2-oxo-2-pyrrolidin-1-ylethyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]propyl}-3-pyridin-4-ylpyrrolidine-1-carboxamide;

or a salt, pro-drug or solvate thereof.

According to a further feature of the first aspect of the invention there is provided a pharmaceutical formulation comprising a compound of Formula (Ib), Formula (Ic), Formula (Id) or preferred compounds of the invention, or salt, pro-drug or solvate thereof, and a pharmaceutically acceptable diluent or carrier.

According to a further feature of the first aspect of the invention there is provided the following uses of a compound of a compound of Formula (Ib), Formula (Ic), Formula (Id) or preferred compounds of the invention, or salt, pro-drug or solvate thereof:

- (a) the use in the manufacture of a medicament for antagonising gonadotropin releasing hormone activity;
- (b) the use in the manufacture of a medicament for administration to a patient, for reducing the secretion of luteinizing hormone by the pituitary gland of the patient; and
- (c) the use in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone related condition in the patient, preferably a sex hormone related condition selected from prostate cancer and premenopausal breast cancer.

The compounds of Formula (I) may be administered in the form of a pro-drug which is broken down in the human or animal body to give a compound of the Formula (I). Examples of pro-drugs include in-vivo hydrolysable esters of a compound of the Formula (I).

Various forms of pro-drugs are known in the art. For examples of such pro-drug derivatives, see:

- 24 -

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985);
 - b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991);
 - c) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
 - d) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); and
 - e) N. Kakeya, et al., Chem Pharm Bull, 32, 692 (1984).
- 10 An in-vivo hydrolysable ester of a compound of the Formula (I) containing a carboxy or a hydroxy group is, for example, a pharmaceutically-acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol. Suitable pharmaceutically-acceptable esters for carboxy include C₁₋₆alkoxymethyl esters for example methoxymethyl, C₁₋₆alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl
- 15 esters, C₃₋₈cycloalkoxycarbonyloxyC₁₋₆alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters, for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters.

An in-vivo hydrolysable ester of a compound of the Formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters (including phosphoramidic

20 cyclic esters) and α -acyloxyalkyl ethers and related compounds which as a result of the in-vivo hydrolysis of the ester breakdown to give the parent hydroxy group/s. Examples of α -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of in-vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give

25 alkyl carbonate esters), dialkylcarbamoyl and N-(dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), dialkylaminoacetyl and carboxyacetyl.

A suitable pharmaceutically-acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example


30 hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically-acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an

- 25 -


organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

- 5 The compounds of Formula (I) can be prepared by a process comprising a step selected from (a) to (f) as follows, these processes are provided as a further feature of the invention:-


(a) Reaction of a compound of formula **XXXII** as follows



- (b) Cleavage of the cyano group of compound of formula **XXXIII** in the presence of acid
10 to produce compound of formula **XXXIV**




(c) Reaction of compound of formula **XXXV** as follows




(d) Reaction of compound of formula **XXXVII** as follows


- 26 -



(e) Reaction of compound of formula **XXXIX** as follows



(f) to form a compound wherein X is nitrogen and Reaction of a compound of formula
5 XXXXI as follows



and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups;
- 10 iii) forming a salt, pro-drug or solvate.

It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups in the starting reagents or intermediate compounds may need to be protected by protecting groups. Thus, the preparation of the compounds of Formula (I) may involve, at an appropriate stage, the
15 addition and subsequent removal of one or more protecting groups.

- 27 -

The protection and de-protection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 2nd edition, T.W. Greene and P.G.M. Wuts, Wiley-Interscience (1991).


5 A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *tert*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The de-protection conditions for the above protecting groups necessarily vary with the choice of
10 protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a *tert*-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an
15 arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

20 A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The de-protection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with
25 a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

 A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis
30 with a base such as sodium hydroxide, or for example a *tert*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.


EXPERIMENTAL**GENERAL REACTION SCHEMES**

In the following schemes wherein Ri, Rii and Riii represent optional substituents on the phenyl ring which are optionally protected as necessary and R represents a protecting group, group **C** has been depicted as substituted phenyl for illustration purposes only. Other definitions of **C** are also appropriate.




Scheme a

Thienopyrroles, such as **3** can be synthesised by the classic Fisher thienopyrrole synthesis reaction by the condensation of a hydrazine-HCl **1** and a ketone **2**, bearing hydrogen atoms α to the carbonyl (Scheme a). Treatment of these reactants in a suitable solvent, such as acetic acid, ethanol, *sec*-butanol, toluene, in the presence of an acid, such as sulphuric, hydrochloric, polyphosphoric and/or a Lewis acid, for example, boron trifluoride, zinc chloride, magnesium bromide, at elevated temperatures (for example 100 °C), gives the desired product. R represents a protecting group, eg *tert*-butylcarbamate or phthalimide.



Scheme b


Thienopyrroles, such as represented in structure **5**, can also be made using aldehydes **4**, bearing hydrogen atoms α to the carbonyl, by cyclization using the conditions above. In **5** this case the substituent at the 2-position must be added later (see scheme d).



Scheme c

- 30 -


Thienopyrrole may also be synthesised utilising the Granburg reaction, wherein a hydrazine **1** is mixed with ketone **6**, bearing a chlorine atom γ to the carbonyl, and heated in a suitable solvent such as ethanol, *sec*-butanol, toluene at a temperature between 50 °C and 120 °C (Scheme c).




Scheme d

The thienopyrrole **5** can be treated with a 'bromine source', such as molecular bromide, pyridinium tribromide, pyrrolidone hydrobromide or polymer supported reagent equivalents, in an inert solvent such as chloroform, methylene chloride at -10 °C to 25 °C to yield the 2-bromo compound **8** (Scheme d). Reaction under Suzuki conditions with a palladium(0) catalyst, a weak base such aqueous sodium carbonate or saturated sodium hydrogen carbonate and the like, and a substituted aryl boronic acid from commercial sources or prepared (as described in: Gronowitz, S.; Hornfeldt, A.-B.; Yang, Y.,-H *Chem. Sci.* **1986**, 26, 311-314), in an inert solvent such as toluene, benzene, dioxane, THF, DMF and the like, with heating between 25 °C and 100 °C, preferably 80 °C, for a period of 1-12 hours, to give the desired compound **3**.

- 31 -




The thiophene **1** can be synthesised by reaction of a hydrazine under the preferred conditions of sodium hydride in DMF at a temperature between -10°C and -5°C , followed by reaction with di-tert-butyl dicarbonate in THF under reflux.



5

Scheme e.

Substituted ketones **2** can be prepared, as outlined in Scheme e starting from appropriate acid chlorides such as **9**. Treatment of the acid chloride with *N,N*-dimethylhydroxylamine hydrochloride in the presence of an amine base such as triethylamine, and a suitable solvent such as methylene chloride at a temperature of -10°C to 25°C , yields the amide **10**. Further reaction with a substituted aryl organolithium (prepared essentially as described in Wakefield B, J.; *Organolithium Methods* Academic Press Limited, **1988**, pp. 27-29 and references therein) in an inert solvent such as tetrahydrofuran, diethyl ether, benzene, toluene or mixture thereof and the like, at a temperature between -100°C and 0°C then quenching of the reaction mixture with a mineral acid such as hydrochloric acid, yields the aryl ketone **2**.



Scheme f.

Commencing with a readily available amino acid with a suitable chain length [a] **11**, the nitrogen atom can be brought in at the beginning of the synthesis by the route shown in


20

- 32 -

Scheme f. Protection of the amine group of **11** with a *tert*-butylcarbamate group is achieved by condensation with di-*tert*-butyl di-carbonate in the presence of an amine base, for example triethylamine, in an inert solvent such as methylene chloride, chloroform, benzene, toluene, tetrahydrofuran and mixtures thereof and the like, at a temperature of -10 °C to 25 °C.

- 5 Coupling of the acid product with *N,N*-dimethylhydroxylamine in the presence of a coupling reagent 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) or 1,3-dicyclohexylcarbodiimide (DCC) or the like, with or without 1-hydroxybenotriazole (HOBt), and suitable amine base, such as triethylamine and the like, in an inert solvent such as methylene chloride, chloroform, dimethylformamide, or mixture thereof, at or near room
- 10 temperature for a period of 3 to 24 hours provided the corresponding coupled product **12**.

Following the same route described above for scheme d, the aryl group can then be installed.




Scheme g.

- Scheme g illustrates another method for the synthesis of ketone such as **2** and **16**, where the nitrogen group is introduced at a latter stage. As above a Weinreb amide **14** can be synthesised from an acid chloride. Treatment with the required amine, in an inert solvent such as THF, toluene, water and the such like can displace the group X to give **17**. As above the aryl group can be introduced by displacement of the Weinreb amide with a suitable aryl lithium nucleophile. Alternatively the nitrogen atom can be introduced already protected as a
- 20 phthalimide by displacement of the group x by potassium phthalimide, or similar salt thereof,

- 33 -

by heating in an inert polar solvent such as DMF, DMSO, THF, toluene with or without the presence of a catalyst such as tetrabutylammonium iodide and the such like, to yield the compound **15**. Again displacement of the Weinreb amide with an organolithium species completes the synthesis of a ketone suitable for cyclization under the Fischer condition

5 described above for thienopyrrole synthesis.




Scheme h.

An alternative approach to a phthalimide protected nitrogen ketone, such as **16**, can be taken by firstly treating a lactone, with an organolithium species as in the above schemes in a

10 suitable solvent such as THF or ether at a low temperature of between -100°C and -50°C to yield a primary alcohol **18** (Scheme h). The hydroxyl function of **18** is replaced with a phthalimide group by a Mitsunobu reaction with an activating agent such as diethyldiazocarboxylate (DEAD), diisopropyldiazocarboxylate or the like with triphenylphosphine, tri-butylphosphine and the like, in an inert solvent such as benzene,

15 toluene, tetrahydrofuran or mixtures thereof to give the desired ketone **16**.




If the group R^1 was not present on the starting hydrazine before cyclization to form an thienopyrrole it may be added post cyclization by an alkylation reaction (**19**→**3**). The thienopyrrole is de-protonated by a strong base, such as sodium hydride, *n*-butyl lithium,

20 lithium diisopropylamine, sodium hydroxide, potassium *tert*-butoxide in a suitable inert

- 34 -

solvent such as THF, DMF, DMSO and the such like, and an alkyl halide added and the mixture stirred at room temperature.



Scheme i


- 5 Depending on the route used above a thienopyrrole **20** suitable for conversion to a cyano-guandine can be formed by removal of the protecting group, for example if a *tert*-butylcarbamate group was used then removal is accomplished using a strong acid, for

- 35 -

example trifluoroacetic acid or hydrochloric acid in an inert solvent such as methylene chloride, chloroform, THF or dioxane at a temperature between -20°C and 25°C . A phthalimide group, for example, can be removed by hydrazine in a suitable solvent for example methanol, ethanol, methylene chloride, chloroform, THF dioxane at a temperature

5 between -20°C and 25°C . The primary amine **20** can be converted to a cyano-guanidine **22** by the two step process of reaction with diphenyl cyanocarbonimide in an inert organic solvent such as *iso*-propyl alcohol, methylene chloride, chloroform, benzene, tetrahydrofuran and the like, at a temperature between -20°C and 50°C , followed by condensation with an appropriately substituted amine in an inert organic from the list above, with heating at a

10 temperature between -20°C and 100°C (Scheme I **20**→**21**→**22**). Further treatment of **22** with 2 molar Hydrochloric acid in methanol at elevated temperature yields guanidine compounds **23**.




Sc

heme j.

15 Similarly, reaction with 1,1'-bis(methylthio)-2-nitroethylene in an inert solvent such as methylene chloride, chloroform, benzene, tetrahydrofuran and the like, followed by condensation with an appropriately substituted amine in an inert organic solvent from the list above yields the nitroethyleneimidazo[1,2-*a*]pyridine **25** (Scheme j, **20**→**24**→**25**).

- 36 -



Scheme k.

Again in a similar fashion the suitable thienopyrrole **20**, derived from de-protection, can be converted to a urea by either direct treatment with an iso-cyanate in an inert solvent such as methylene chloride, chloroform or THF and the such like, or by a two step procedure of reaction with triphosgene (**20**→**27**) followed by addition of an amine (**27**→**26**), bearing the required substitution to yield **26**.

EXAMPLES

The invention will now be illustrated with the following non-limiting Examples in which, unless otherwise stated:

- (i) evaporations were carried out by rotary evaporation *in vacuo* and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) operations were carried out at room temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen;

- 37 -

(iii) yields are given for illustration only and are not necessarily the maximum attainable;

(iv) the structures of the end-products of the Formula (I) were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic
5 resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin, quintet;

(v) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC),
10 infra-red (IR) or NMR analysis;

(vi) chromatography was performed on silica (Merck Kieselgel: Art.9385);

(vii) isolute™ refers to silica (SiO₂) based columns with irregular particles with an average size of 50µm with nominal 60 Å porosity [Source: Jones Chromatography, Ltd., Glamorgan, Wales, United Kingdom].

15

Abbreviations


brine	a saturated solution of sodium chloride in distilled water
DCC	1,3-dicyclohexylcarbodiimide
DEAD	diethyldiazocarbonylate
20 DMSO	Dimethyl sulphoxide
DMF	dimethylformamide
EDC	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
HOBt	1-hydroxybenotriazole
25 IPA	isopropyl alcohol
RM	reaction mixture
RT	room temperature
THF	tetrahydrofuran

30

- 38 -

Starting Materials

The starting materials were prepared as follows:



To a suspension of NaH (54 g; 1.35 mol), and 18-crown-6 in THF (2 l) stirred at ambient temperature under argon atmosphere, **1** (100 g; 0.588 mol) was added over a period of 30 minutes. After stirring overnight, the mixture was cooled at 0°C and methyl iodide was added dropwise. The mixture was stirred at 18°C for 3 hours, poured into a saturated solution of NH₄Cl and extracted with AcOEt. The organic phase was evaporated and purified by flash chromatography eluting with petroleum ether / ethyl acetate 95/5 to give **2** as an oil.

10 Yield: 90 %

¹H NMR (CDCl₃): 1.20 (t, 3H); 1.63 (s, 6H) ; 4.10 (q, 2H) ; 6.92 (m, 2H) ; 7.17 (m, 1H).

Nitronium tetrafluoroborate (77.9 g; 0.586 mol) was added at -55°C to a solution of **2** (105.6 g; 0.583 mol) in DME (1.5 l). The mixture was allowed to warm up at -10°C over 4 hours. After extraction with ethyl acetate, the organic phase was purified by flash chromatography, eluting with petroleum ether / AcOEt 95/5 to give **3**.

Yield: 86 %

¹H NMR (CDCl₃): 1.23 (t, 3H); 1.65 (s, 6H); 4.14 (q, 2H); 6.90 (d, 1H); 7.75 (d, 1H).

20 A suspension of **3** (101.7 g; 0.41 mol) and 10 % Pd/C (15 g) in a mixture of ethanol (700 ml) and ethyl acetate (300 ml) was hydrogenated under hydrogen atmosphere (5 bars) for 5 hours. After filtration of the catalyst on celite, the residue was evaporated and redissolved in THF (900 ml); di-tert-butyl dicarbonate (100 g; 0.46 mol) was added and the

- 39 -

mixture was refluxed for 16 hours. After evaporation of the solvents, the resulting solid was taken up in petroleum ether and filtered to give **5**.

Yield: 68 %

¹H NMR (CDCl₃): 1.20 (t, 3H); 1.48 (s, 9H); 1.58 (s, 6H); 4.10 (q, 2H); 6.30 (m, 1H); 6.60 (m, 1H).

A solution of **5** (50 g; 0.16 mol) and 2N NaOH (160 ml) in ethanol (300 ml) was refluxed for 1 h 30. After evaporation to dryness, the residue was partitioned between water and ether. The aqueous layer was acidified with saturated citric acid and extraction with ethyl acetate to give after evaporation a solid, which was triturated in pentane and filtered to give **6** as a solid.

Yield: 100%

¹H NMR (DMSO-d₆): 1.48 (m, 15H); 6.30 (d, 1H); 6.59 (d, 1H).

A solution of **6** (20.1 g; 0.07 mol), EDCI (20.1 g; 0.105 mol) and DMAP (2.56 g; 0.021 mol) in dichloromethane (200 ml) was stirred under argon atmosphere for 10 minutes. Pyrrolidine (11.69 ml; 0.14 mol) was then added and the mixture was stirred overnight at ambient temperature. After evaporation to dryness, the residue was purified by flash chromatography eluting with AcOEt / petroleum ether 40/60 to give after trituration in ether / pentane **7** as a solid.

¹H NMR (CDCl₃): 1.51 and 1.57 (s, 15 H); 1.7 (m, 4H); 3.03 (br, 2H); 3.50 (br, 2H); 6.35 (d, 1H); 6.48 (d, 1H); 7.26 (br, 1H).

7 (17 g; 0.05 mol) was added under argon atmosphere to a suspension of NaH 60 % (2.42 g; 0.06 mol) in dioxan (240 ml). The mixture was stirred at 100°C for 3 hours. After cooling to 10°C, **8** (10.1 g; 0.055 mol) was added. The reaction mixture was stirred at ambient temperature overnight. After filtration of the insoluble, the filtrate was evaporated and purified by flash chromatography, eluting with AcOEt / petroleum ether 45/55 to give **9** as a white solid.

Yield: 89.5 %

¹H NMR (CDCl₃): 1.55 and 1.57 (s, 15 H); 1.71 (s, 4H); 3.04 (s, 2H); 3.50 (s, 2H); 6.53 (d, 2H); 6.70 (s, 2H).

- 40 -

A solution of **9** hydrochloride salt (4 g; 0.0102 mol) and **10** (6.6 g; 0.0205 mol) in AcOH (20 ml) was heated at 120°C under argon atmosphere for 3 hours. The reaction mixture was diluted with saturated NH₄Cl and extracted with AcOEt. After evaporation, the crude was purified by flash chromatography eluting with AcOEt / petroleum ether 50/50 to give **11** as a
5 foam.

Yield: 53 %

MS-ESI : 540 [M+H]⁺

¹H NMR (CDCl₃): 1.53 and 1.58 (s, 6H); 1.69 (s, 4H); 2.29 (s, 6H); 3.12 (m, 4H); 3.52 (s, 2H); 3.91 (m, 2H); 6.80 (m, 2H); 7.02 (s, 2H); 7.6-7.8 (m, 4H); 8.10 (s, 1H).

10

A solution of **11** (0.534 g; 0.99 mmol) and hydrazine (1 ml) in a mixture of EtOH (2 ml) and CH₂Cl₂ (2 ml) was stirred under argon atmosphere at ambient temperature overnight. After evaporation, the crude was extracted in a mixture of CH₂Cl₂ and saturated NaHCO₃. The organic layer was evaporated to give **12** as a foam.

15 Yield: 90 %

¹H NMR (CDCl₃): 1.52 and 1.62 (s, 6H); 1.69 (s, 4H); 2.33 (s, 6H); 2.80-3.2 (m, 6H); 3.52 (m, 2H); 6.74 (s, 1H); 6.93 (s, 1H); 7.05 (s, 2H); 8.15 (s, 1H).

MS-ESI: 410 [M+H]⁺

20


- 41 -

Example 1.0

***N'*-cyano-*N*-{2-[2-(1,1-dimethyl-2-oxo-2-pyrrolidin-1-ylethyl)-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]ethyl}-3-pyridin-4-ylpyrrolidine-1-carboximidamide**

Example 1.1

- 5 ***N*-{2-[2-(1,1-dimethyl-2-oxo-2-pyrrolidin-1-ylethyl)-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrol-4-yl]ethyl}-3-pyridin-4-ylpyrrolidine-1-carboximidamide**

**Example 1.0****Example 1.1**

A solution of **16** (0.160 g; 0.26 mmol) in a mixture of MeOH (8 ml) and 2N HCl (8 ml) was heated at 70°C for 18 hours.

After neutralisation with diluted NH₄OH, the mixture was extracted with AcOEt / PrOH 10/3. The organic layer was evaporated and purified by flash chromatography eluting with a gradient 5-20% 3.5N-NH₃-MeOH / CH₂Cl₂ to give **Example 1.1**.

Yield: 20 %

15 MS-ESI: 583 [M+H]⁺

¹H NMR (DMSO d₆) : 1.53 (s, 6H) ; 1.64 (m br, 4H) ; 2-2.15 (m, 1H) ; 2.3 (s, 6H) ; 2.4-2.5 (m br, 1H) ; 3-3.10 (m, 4H) ; 3.35-3.5 (m, 7H) ; 3.8 (m br, 2H) ; 6.83 (s, 1H) ; 6.91 (s, 1H) ; 7.09 (s, 2H).

20 The starting material was prepared as follows:

A solution of **12** (0.527 g; 1.288 mmol) and diphenyl-*N*-cyanocarbonimidate (0.522 g; 2.19 mmol) in isopropanol (10 ml) was stirred at ambient temperature under argon atmosphere for 20 hours. After evaporation to dryness, the crude was purified by flash chromatography, eluting with petroleum ether / AcOEt 80/20 to give **15**.

- 42 -

Yield: 56 %.

MS-ESI: 554 [M+H]⁺

A mixture of **15** (0.38 g; 0.68 mmol) and 4-pyrrolidin-3-yl pyridine (0.38 g; 2.5 mmol) in isopropanol was refluxed under argon atmosphere for 20 hours. After evaporation to dryness, the mixture was purified by flash chromatography, eluting with a gradient 4-8 % MeOH / CH₂Cl₂ to give **Example 1.0**.



Yield: 66 %.

MS-ESI: 606 [M-H]⁻




¹H NMR (CDCl₃): 1.62 (s, 6H) ; 1.6-1.7 (m br, 4H) ; 1.85-2 (m, 1H) ; 2.2-2.35 (m, 1H) ; 2.3 (s, 6H) ; 3.05-3.8 (m, 13 H) ; 4.4 (t, 1H NH) ; 6.73 (s, 1H) ; 6.88 (s, 1H) ; 7.04 (d, 2H) ; 7.05 (s, 2H) ; 8.47 (s, 1H 1NH) ; 8.52 (d, 2H).

Examples 1.2 – 1.6

Following a procedure similar to that described in example 1, the following compounds were prepared.


Example		MS-ESI
1.2		648 [M+H] ⁺
1.3		623 [M+H] ⁺

- 43 -

Example		MS-ESI
1.4		648 [M+H] ⁺
1.5		634 [M+H] ⁺
1.6		609 [M+H] ⁺

Example 2

2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
 4-[1S-methyl-2-(N'-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido)
 5 ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-b]pyrrole



To a solution of **19** (0.325 g; 0.54 mmol) in CH₂Cl₂ (10 ml) at 0°C was added under argon atmosphere 4-pyrrolidin-3-yl pyridine (0.122 g; 0.82 mmol), EDC (0.158 g; 0.82 mmol) and DIEA (0.142 ml; 0.82 mmol). The mixture was stirred at 0°C for 15 minutes allowed to warm
 10 up and stirred for 24 hours at ambient temperature. The reaction mixture was extracted with CH₂Cl₂. The organic layer was evaporated and the crude material was purified by flash chromatography eluting with AcOEt and MeOH-NH₃ 97.5/2.5 95/5 to give **Example 2** as a solid.

Yield: 55 %.

- 44 -

^1H NMR (CDCl_3): 1.2 (m, 6H); 1.2-1.3 (m, 4H); 1.4 (m, 3H); 1.5-1.68 (m, 4H); 1.55 (s, 6H); 1.7-1.9 (m, 1H); 2.1-2.2 (m, 1H); 2.28 (m, 6H); 3.02-3.5 (m, 7H); 3.6 (m, 1H); 4.05 (s broad, 1H); 4.7 (s broad, 1H); 4.82 (m, 1H); 6.72 (s, 1H); 6.9 (m, 1H); 7.0 (s, 1H); 7.05 (d, 2H); 8.20 (s, 1H); 8.50 (d, 2H)

5 MS-ESI: $[\text{M}+\text{H}]^+$ 709

The starting material was prepared as follows:

To a solution of **21** (0.098 g; 0.66 mmol) in CH_2Cl_2 (1.5 ml) was added at 0°C , a solution of **20** (0.3 g; 0.66 mmol) in CH_2Cl_2 (1.5 ml). The mixture was stirred at ambient temperature for
10 90 minutes and extracted. The organic layer was evaporated and purified by flash chromatography, eluting with CH_2Cl_2 / AcOEt 50/50 to give **19**.

Yield: 90 %

^1H NMR (CDCl_3): 1.2 (m, 6H); 1.2-1.35 (m, 4H); 1.38 (d, 3H); 1.50-1.80 (m, 4H); 1.55 (s, 6H); 2.35 (s, 6H); 3.45 (m, 1H); 1.78 (m, 1H); 4.00 (m, 1H); 4.10 (s broad 1H); 4.75 (s broad,
15 1H); 4.87 (m, 1H); 6.80 (s, 1H); 6.96 (s, 1H); 7.07 (s, 2H); 7.72 (s, 1H); 8.10 (s, 1H); 9.54 (s, 1H).


MS-ESI: $[\text{M}+\text{H}]^+$ 595

Preparation of **20** is described in **Example 8**.







20

Examples 2.1 - 2.7







Following a procedure similar to that described in example 3, the following examples were prepared.

Example		MS-ESI
2.1		695 $[\text{M}+\text{H}]^+$

- 45 -


Example		MS-ESI
2.2		683 [M+H] ⁺
2.3		655 [M+H] ⁺
2.4		657 [M+H] ⁺
2.5		611 [M+H] ⁺
2.6		658 [M+H] ⁺
2.7		629 [M+H] ⁺

- 46 -

Example		MS-ESI
2.8		724 [M+H] ⁺
2.9		709 [M+H] ⁺
2.10		724 [M+H] ⁺
2.11		724 M+H] ⁺
2.12		730 M+H] ⁺
2.13		746 M+H] ⁺

Example 3

**2-(1,1-dimethyl-2-oxo-2-pyrrolidin-1-ylethyl)-4-[1S-methyl-2-(3-{pyridin-4-yl}pyrrolidin-1-yl)carbonylamino-ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-
5 b]pyrrole**



22

Example 3

4-nitrophenyl chloroformate (0.127 g ; 0.63 mmol) was added under argon atmosphere, at 0°C to a solution of **22** (0.254 g ; 0.60 mmol) and triethylamine –0.088 ml ; 0.63 mmol) in methylene chloride (4 ml). The mixture was stirred at 0°C for 30 minutes and at ambient
10 temperature for 1 hour. 4-pyrrolidin-3-yl pyridine (0.098 g ; 0.72 mmol) in solution in methylene chloride (0.5 ml) was added. The mixture was stirred for 2 hours and purified by flash chromatography eluting with a gradient 2-6 % MeOH/CH₂Cl₂ to give Example 3 as a solid.

Yield : 80 %

15 MS-ESI : 598 [M+H]⁺







¹HNMR (CDCl₃) : 1.37 (d, 3H) ; 1.6 (s, 6H) ; 1.6-1.75 (m, 4H) ; 1.75-2 (m, 1H) ; 2.2-2.3 (m, 1H) ; 2.29 (s, 6H) ; 3-3.4 (m, 8H) ; 3.45-3.8 (m, 4H) ; 4.12 (m, 1H, NH) ; 6.77 (s, 1H) ; 6.91 (m, 1H) ; 7-7.1 (m, 4H) ; 8.28 (s, 1H, NH) ; 8.48 (s, br, 2H).

20 **22** was prepared following a procedure similar to that described in example 1 for compound **12**.

Examples 3.1 – 3.5

Following a procedure similar to that described in example 4, the following examples were
25 prepared.

- 48 -


Example		MS-ESI
3.1		572 [M+H] ⁺
3.2		574 [M+H] ⁺
3.3		607 [M+H] ⁺
3.4		520 [M+H] ⁺
3.5		624 [M+H] ⁺
3.6		638 [M+H] ⁺

- 49 -

Example 4

**2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1S-methyl-2-(N'-ethoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido)
ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-*b*]pyrrole**

5 **Example 4** was prepared following a procedure similar to that described in example 2.




Yield: 63%

^1H NMR (CDCl_3) 1.25 (multiplet, 3H) ; 1.25 – 1.38 (m, 6H) ; 1.43 (multiplet, 3H) ; 1.62 (s, 6H) ; 1.45 - 2.20 (multiplets , 5H) ; 2.32 (s, 6H) ; 3.00 -3.55 (multiplets , 7H) ; 3.65 (10 multiplet ,1H) ; 4.1 (sb, 1H) ; 4.07 (multiplet, 2H) ; ; 4.80 (sb, 1H) ; 6.75 (s, 1H) ; 6.93 (d, 1H) ; 7.02 (m, 3H) ; 7.07 (d, 1H) ; 8.27 (s, 1H) ; 8.51 (multiplet, 2H) .

MS-ESI :695 $[\text{M}+\text{H}]^+$

The starting material was prepared as follows:



15

To a solution of **24** (0.350 g; 2.66 mmol) in CH_2Cl_2 (8 ml) was added at 0°C , a solution of **20** (1.5 g; 2.66 mmol) and DIEA (0.463 ml; 2.66 mmol) in CH_2Cl_2 (8 ml). The mixture was stirred at ambient temperature for 2 hours. After evaporation, the residue was purified by flash chromatography, eluting successively with CH_2Cl_2 and CH_2Cl_2 / AcOEt 585/15 to give **23**.

20 Yield: 100 %

- 50 -


^1H NMR (CDCl_3) 1.209 (t, 3H) ; 1.25 – 1.55 (m, 4H) ; 1.45 – 1.80 (m, 4H) ; 1.627 (d, 3H) ; 1.591 (s, 6H) ; 2.355 (s, 6H) ; 3.473 (multiplet , 1H) ; 3.770 (multiplet , 1H) ; 4.05 (quintuplet, 1H) ; 4.1 (sb, 1H) ; 4.130 (quadruplet, 2H) ; ; 4.85 (sb, 1H) ; 6.806 (s, 1H) ; 6.968 (s, 1H) ; 7.069 (s, 2H) ; 7.799 (s, 1H) 8.129 (s, 1H) ; 9.55 (s, 1H) .

5

Example 5

2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-

4-[1S-methyl-2-(N'-isoethoxycarbonyl-4-{morpholinocarbonyl}piperazin-1-yl
carboximidamido)ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-*b*]pyrrole



24

Example 5

10

To a mixture of **24** (0.095 g; 0.15 mmol) and K_2CO_3 (0.23g; 0.165 mmol) in CH_3CN (3ml) was added under argon atmosphere, **25** (0.025g; 0.165 mmol). The mixture was stirred at ambient temperature for 20 hours. After evaporation to dryness, the residue was purified by flash chromatography, eluting successively with CH_2Cl_2 , CH_2Cl_2 / AcOEt 50/50 and NH_3 /

15 AcOEt 2/98 to give after trituration in ether:pentane Example 5 as a solid.

Yield: 72%.


^1H RMN (CDCl_3) 1.270 (t, 3H) ; 1.20 – 1.35 (m, 4H) ; 1.392 (d, 3H) ; 1.45 – 1.75 (m, 4H) ; 1.604 (s, 6H) ; 2.352 (s, 6H) ; 3.132 – 3.32 (multiplets , 15H) ; 3.67 (multiplet , 4H) ; 4.025 (quadruplet, 2H) ; 4.05 (sb, 1H) ; 4.75 (sb, 1H) ; 6.736 (s, 1H) ; 6.968 (s, 1H) ; 7.020 (s, 2H) ; 7.965 (s, 1H) ; 8.217 (s, 1H) .

20

MS-ESI : 746 $[\text{M}+\text{H}]^+$

- 51 -

The starting material was prepared as follows



To a solution of **23** (0.156 g; 0.27 mmol) in CH_2Cl_2 (6 ml) at 0°C was added under argon atmosphere **27** (0.076 g; 0.405 mmol), EDC (0.078 g; 0.405 mmol) and DIEA (0.07 ml; 0.405 mmol). The mixture was stirred at 0°C for 15 minutes allowed to warm up and stirred for 24 hours at ambient temperature. The reaction mixture was extracted with CH_2Cl_2 . The organic layer was evaporated and the crude material was purified by flash chromatography eluting successively with methylene chloride, methylene chloride / AcOEt 50/50 and 3.5 N NH_3 MeOH / AcOEt 5/95 to give **26** as a solid.

10 Yield: 58%

^1H NMR (CDCl_3) 1.235 (t, 3H); 1.20 – 1.35 (m, 4H); 1.396 (d, 3H); 1.450 (s, 9H); 1.55 – 1.75 (m, 4H); 1.598 (s, 6H); 2.352 (s, 6H); 3.131 – 3.379 (multiplets, 11H); 4.025 (quadruplet, 2H); 4.05 (sb, 1H); 4.75 (sb, 1H); 6.744 (s, 1H); 6.970 (s, 1H); 7.017 (s, 2H); 7.92 (s, 1H);
 15 8.188 (s, 1H).


26 (0.06g; 0.82 mmol) was dissolved in methylene chloride (0.6 ml) and treated with a solution made of 12N HCl / dioxan 5/25 (1 ml). The mixture stirred under argon atmosphere overnight. After evaporation to dryness, the residue was neutralised and extracted with
 20 AcOEt. The organic layer was separated, dried and evaporated to dryness. The residue was triturated with methylene chloride / ether to give **27** triturated in a mixture of MeOH, methylene chloride and ether to give **24** as solid.

Yield : 88%

^1H RMN (CDCl_3) 1.235 (t, 3H); 1.20 – 1.35 (m, 4H); 1.33 (d, 3H); 1.45 – 1.75 (m, 4H); 1.62
 25 (s, 6H); 2.35 (s, 6H); 2.85 (multiplet, 4H); 3.26 – 3.38 (multiplets, 7H); 4.025 (quadruplet, 2H); 4.05 (sb, 1H); 4.75 (sb, 1H); 6.74 (s, 1H); 6.96 (s, 1H); 7.02 (s, 2H); 8.01 (s, 1H); 8.41 (s, 1H); + 1 NH.

Example 6

2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
 4-[1S-methyl-2-(N'-aminocarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido)
 5 ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-b]pyrrole



To a stirred solution of **28** (0.39 g; 0.603 mmol) in THF (5 ml) at room temperature, was added a 18% (v/v) aqueous solution of HCl. The resulting yellow solution was heated at 80°C for 4 hours after which HPLC showed no remaining starting material. The reaction mixture was allowed to cool down to room temperature and concentrated on a rotary evaporator. A solution of saturated aqueous brine (5 ml) and saturated aqueous NaHCO₃ (5 ml) were added and the resulting oil was extracted with DCM (100 ml). The organic layer was separated, washed with brine (10 ml), dried over magnesium sulfate and concentrated to afford an orange gum. The gum was dissolved in DCM (1 ml) and purified by flash chromatography on silica gel eluting with DCM-MeOH (95:5) to afford the **Example 6** (0.067 g).

Yield: 16.8%.

¹H NMR (CDCl₃) (δ ppm) 1.22 – 1.75 (m, 15H); 1.88-1.94 (m, 1H); 2.15-2.47 (m, 9H); 3.23 - 3.73 (m, 8H); 4.07 (sb, 1H); 4.76 (sb, 1H); 6.74 (m, 1H); 6.97 (m, 1H); 6.98-7.11 (m, 4H); 8.56 (m, 2H).


MS-ESI : 666 [M+H]⁺

- 53 -

The intermediate **24** was prepared using similar chemistry than that used for the preparation of **Example 1.0**.

5 **Example 7**

**2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1*S*-methyl-2-(*N*'-methylcarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido)
ethyl]-5-(3,5-dimethylphenyl)-6*H*-thieno[2,3-*b*]pyrrole**



- 10 To a stirred solution of **29** (0.193 g; 0.351 mmol), DIPEA (0.068 g; 0.527 mmol) and 4-pyrrolidin-3-yl pyridine (0.057 g; 0.386 mmol) in DMF (1 ml) at room temperature, was added solid EDCI (0.074 g; 0.386 mmol). The reaction mixture was heated at 80°C for 16 hours after which HPLC showed no remaining starting material. The reaction mixture was cooled to room temperature, triturated with water (5 ml) and the resulting solid was collected
- 15 by filtration, dissolved in DCM (2 ml) and purified by flash chromatography on silica gel eluting with DCM-MeOH (97:3) to afford **Example 7** (0.03 g).

Yield: 12%.


¹H NMR (CDCl₃) (δ ppm) 1.22 – 1.37 (m, 7H); 1.43 (m, 2H); 1.52-1.74 (m, 8H); 1.88-1.94 (m, 1H); 2.06 (m, 3H); 2.19-2.42 (m, 8H); 3.23 - 3.41 (m, 5H); 3.57 (m, 2H); 4.07 (sb, 1H); 4.73 (sb, 1H); 6.77 (s, 1H); 6.96 (m, 1H); 7.04-7.11 (m, 4H); 8.27 (s, 1H); 8.53 (m, 2H).

20

MS-ESI: 665 [M+H]⁺

The intermediate **29** was prepared using similar chemistry than that described for the preparation of intermediate **19**.

- 54 -

Example 8**2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-****4-[1S-methyl-2-(N'-hydroxy-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido) ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-b]pyrrole**

5

30

Example 8

To a stirred solution of **30** (0.152g; 0.173 mmol) in diethyl ether (5 ml) at 0°C, were added MeOH (1 ml) and a 4.0M solution of HCl in 1,4-dioxane (5 ml). The solvent was evaporated to dryness and the residue was suspended in toluene and evaporated to dryness again and further dried under high vacuum. The resulting white foam was triturated with diethyl ether
 10 (20 ml) and the resulting white solid collected by filtration, washed with diethyl ether (2 x 5 ml) and dried to a constant weight to afford **Example 8.HCl** (0.106g) as a white solid.


Yield: 85.4%.

¹H NMR (DMSO-d₆) (δ ppm) 1.32 (m, 7H); 1.52 (m, 10H); 1.84-2.04 (m, 4H); 2.25-2.32 (m, 6H); 3.23 - 3.72 (m, 8H); 4.03 (sb, 1H); 4.45 (sb, 1H); 6.84-7.93 (m, 2H); 7.05 (m,
 15 2H); 7.35 (m, 1H); 7.53 (m, 1H); 7.66 (m, 1H); 7.74 (m, 1H); 8.79 (m, 2H); 10.11-10.19 (m, 1H); 10.55-10.63 (m, 1H); 11.38 (m, 1H).

MS-ESI : 639 [M+H]⁺

- 55 -

The intermediate **30** was prepared as follows:



The intermediate **35** was prepared using similar chemistry to that used for the preparation of **9**.

- 5 To a stirred suspension of **35** (17 g ; 45.0 mmol) and **34** (22.5 g ; 67.0 mmol) in 2-butanol (50 ml) was added a 4M solution of HCl in 1,4-dioxane (22.5 ml ; 90.0 mmol). The resulting thick suspension was heated at 90°C for 1 hour after which HPLC showed no remaining starting material. The resulting dark brown solution was evaporated to dryness on a rotary evaporator and the residue was dissolved in DCM and purified by flash chromatography on
- 10 silica gel eluting with ethyl acetate-petroleum ether 40/60 (10:90 to 50/50) to afford **33** (16 g) as a white solid.

Yield: 54%

¹H NMR (CDCl₃) (δ ppm) 1.26 – 1.40 (m, 7H) ; 1.57 (s, 6H) ; 1.63 – 1.83 (m, 4H) ; 2.32 (s, 6H) ; 3.66 (m, 1H) ; 3.87 (m, 2H) ; 4.20 (sb, 1H) ; 4.75 (sb, 1H) ; 6.86 (s, 1H) ; 6.92 (s, 1H) ; 6.98 (s, 2H) ; 7.67 (m, 2H) ; 7.74 (m, 2H) ; 8.03 (s, 1H) .

MS-ESI: 580 [M+H]⁺

To a stirred suspension of **33** (14 g ; 24.0 mmol) in ethanol (300 ml) at room temperature, was added neat hydrazine monohydrate (12 ml ; 240 mmol). The reaction mixture was stirred at

20 room temperature for 16 hours after which HPLC showed no remaining starting material. The

- 56 -

resulting precipitate was collected by filtration, washed with ethanol (2 x 20 ml) and the filtrate was evaporated to dryness on a rotary evaporator and dried to a constant weight under high vacuum to afford **20** (10.9 g) as a yellow foam which was used without further purification.

5 Yield: 100%

MS-ESI: 450 [M+H]⁺

¹H NMR (CDCl₃) (δ ppm) 1.27 – 1.36 (m, 7H); 1.43-1.53 (m, 10H); 2.34 (s, 6H); 3.06 (m, 1H); 3.23 (m, 1H); 3.28 (m, 1H); 4.10 (sb, 1H); 4.50 (sb, 1H); 6.87 (s, 1H); 6.96 (s, 1H); 7.07 (s, 2H).

10

To a stirred solution of 1,1'-thiocarbonyldiimidazole (0.08 g; 0.45 mmol) in MeCN (5 ml) at 0°C, was added a solution of **20** (0.20 g; 0.45 mmol) and DIPEA (0.058g; 0.45 mmol) in DCM (5 ml). The resulting solution was stirred at room temperature for 1 hour after which HPLC showed no remaining starting material. A 50% (v/v) solution of hydroxylamine in

15 water (0.297 g; 9.00 mmol) was added and the resulting solution was stirred at room temperature for 2 hours after which HPLC showed no remaining starting material. The reaction mixture was evaporated to dryness and the residue was purified by flash chromatography on silica gel eluting with DCM-MeCN (70:30) to afford **32** (0.160 g) as a beige foam.

20 Yield: 67.8%.

MS-ESI : 525 [M+H]⁺

To a stirred solution of **32** (0.20 g; 0.38 mmol) and triethylamine (0.058 g; 0.57 mmol) in DCM (10 ml) at room temperature, was added triphenylmethyl chloride (0.117 g; 0.42 mmol).

25 The resulting solution was stirred at room temperature for 1 hour after which HPLC showed no remaining starting material. The solvent was evaporated on a rotary evaporator and the residue was purified by flash chromatography on silica gel eluting with DCM-MeCN (80:20) to afford **31** (0.198 g) as a white foam.

Yield: 68%.

30 MS-ESI : 767 [M+H]⁺

To a stirred solution of **31** (0.198 g; 0.26 mmol), DIPEA (0.050 g; 0.39 mmol) and 4-pyrrolidin-3-yl pyridine (0.039 g; 0.26 mmol) in DCM (2 ml) at room temperature, was

- 57 -

added solid EDCI (0.075 g; 0.39 mmol). The reaction mixture was stirred at room temperature for 16 hours after which HPLC showed no remaining starting material. The reaction mixture was purified by flash chromatography on silica gel eluting with DCM-MeCN (90:10) to afford **30** (0.192 g) as a pale yellow foam.


5 Yield: 83.8%.

MS-ESI : 881 [M+H]⁺

Example 9

2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-

10 4-[1S-methyl-2-(N'-methoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido)ethyl]-5-(3,5-dimethylphenyl)--6H-thieno[2,3-b]pyrrole



Example 9

Example 9 was prepared using similar chemistry to that described for **example 8**.

Yield: 52%.

15 ¹H NMR (CDCl₃) (δ ppm) 1.22 – 1.43 (m, 7H); 1.52-1.73 (m, 10H); 1.79-1.92 (m, 2H); 2.25 (m, 2H); 2.36 (s, 6H); 3.23 - 3.28 (m, 6H); 3.46 (m, 3H); 4.03 (sb, 1H); 4.75 (sb, 1H); 6.74 (s, 1H); 6.96 (s, 1H); 7.07 (s, 2H); 7.12 (d, 1H); 7.16 (d, 1H); 8.15 (s, 1H); 8.53 (m, 2H).

MS-ESI : 653 [M+H]⁺

20

THERAPEUTIC USES

Compounds of Formula (I) are provided as medicaments for antagonising gonadotropin releasing hormone (GnRH) activity in a patient, eg, in men and/or women. To this end, a compound of Formula (I) can be provided as part of a pharmaceutical formulation which also includes a pharmaceutically acceptable diluent or carrier (eg, water). The formulation may be in the form of tablets, capsules, granules, powders, syrups, emulsions (eg, lipid emulsions), suppositories, ointments, creams, drops, suspensions (eg, aqueous or oily suspensions) or solutions (eg, aqueous or oily solutions). If desired, the formulation may

- 58 -

include one or more additional substances independently selected from stabilising agents, wetting agents, emulsifying agents, buffers, lactose, sialic acid, magnesium stearate, terra alba, sucrose, corn starch, talc, gelatin, agar, pectin, peanut oil, olive oil, cacao butter and ethylene glycol.

5 The compound is preferably orally administered to a patient, but other routes of administration are possible, such as parenteral or rectal administration. For intravenous, subcutaneous or intramuscular administration, the patient may receive a daily dose of 0.1mgkg^{-1} to 30mgkg^{-1} (preferably, 5mgkg^{-1} to 20mgkg^{-1}) of the compound, the compound being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular
10 dose may be given by means of a bolus injection. Alternatively, the intravenous dose may be given by continuous infusion over a period of time. Alternatively, the patient may receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day. A suitable pharmaceutical formulation is one suitable for oral administration in unit dosage form, for example as a tablet or capsule,
15 which contains between 10mg and 1g (preferably, 100 mg and 1g) of the compound of the invention.

Buffers, pharmaceutically acceptable co-solvents (eg, polyethylene glycol, propylene glycol, glycerol or EtOH) or complexing agents such as hydroxy-propyl β cyclodextrin may be used to aid formulation.

20 One aspect of the invention relates to the use of compounds according to the invention for reducing the secretion of LH and/or FSH by the pituitary gland of a patient. In this respect, the reduction may be by way of a reduction in biosynthesis of the LH and FSH and/or a reduction in the release of LH and FSH by the pituitary gland. Thus, compounds according to the invention can be used for therapeutically treating and/or preventing a sex hormone
25 related condition in the patient. By "preventing" we mean reducing the patient's risk of contracting the condition. By "treating" we mean eradicating the condition or reducing its severity in the patient. Examples of sex hormone related conditions are: a sex hormone dependent cancer, benign prostatic hypertrophy, myoma of the uterus, endometriosis, polycystic ovarian disease, uterine fibroids, prostatauxe, myoma uteri, hirsutism and
30 precocious puberty. Examples of sex hormone dependent cancers are: prostatic cancer, uterine cancer, breast cancer and pituitary gonadotrophe adenoma.

The compounds of the invention may be used in combination with other drugs and therapies used to treat / prevent sex-hormone related conditions.

- 59 -

If formulated as a fixed dose such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically-active agent within its approved dosage range. Sequential use is contemplated when a combination formulation is inappropriate.

5 In the field of medical oncology examples of such combinations include combinations with the following categories of therapeutic agent:

- i) anti-angiogenic agents (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function, angiostatin, endostatin, razoxin, thalidomide) and including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (RTKIs) (for example those
10 described in international patent applications publication nos. WO-97/22596, WO-97/30035, WO-97/32856 and WO-98/13354, the entire disclosure of which documents is incorporated herein by reference);
- ii) cytostatic agents such as anti-oestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, idoxifene), progestogens (for example megestrol
15 acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole, exemestane), anti-progestogens, anti-androgens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), inhibitors of testosterone 5α -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function) and inhibitors of growth factor function,
20 (such growth factors include for example epidermal growth factor (EGF), platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors);
- iii) biological response modifiers (for example interferon);
- 25 iv) antibodies (for example edrecolomab); and
- v) anti-proliferative/anti-neoplastic drugs and combinations thereof, as used in medical oncology, such as anti-metabolites (for example anti-folates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside); anti-tumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin
30 and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); anti-mitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); enzymes

- 60 -

(for example asparaginase); thymidylate synthase inhibitors (for example raltitrexed); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan, irinotecan).

The compounds of the invention may also be used in combination with surgery or
5 radiotherapy.

ASSAYS

The ability of compounds according to the invention to act as antagonists of GnRH can be determined using the following in vitro assays.

10 Binding Assay Using Rat pituitary GnRH Receptor

The assay is performed as follows:-

1. Incubate crude plasma membranes prepared from rat pituitary tissues in a Tris.HCl buffer (pH. 7.5, 50 mM) containing bovine serum albumin (0.1%), [I-125]D-t-Bu-Ser6-Pro9-ethyl amide-GnRH, and the test compound. Incubation is at 4°C for 90 minutes to 2
15 hours.
2. Rapidly filter and repeatedly wash through a glass fibre filter.
3. Determine the radioactivity of membrane bound radio-ligands using a gamma counter.

From this data, the IC₅₀ of the test compound can be determined as the concentration of the compound required to inhibit radio-ligand binding to GnRH receptors by 50%.

- 20 Compounds according to the present invention have activity at a concentration from 1nM to 5 µM.

Binding Assay Using Human GnRH Receptor

- Crude membranes prepared from CHO cells expressing human GnRH receptors are
25 sources for the GnRH receptor. The binding activity of compounds according to the invention can be determined as an IC₅₀ which is the compound concentration required to inhibit the specific binding of [¹²⁵I]buserelin to GnRH receptors by 50%. [¹²⁵I]Buserelin (a peptide GnRH analogue) is used here as a radiolabelled ligand of the receptor.

30 Assay to Determine Inhibition of LH release

The LH release assay can be used to demonstrate antagonist activity of compounds, as demonstrated by a reduction in GnRH-induced LH release.

Preparation of Pituitary Glands

Pituitary glands obtained from rats are prepared as follows. Suitable rats are Wistar male rats (150-200g) which have been maintained at a constant temperature (eg, 25°C) on a 12 hour light/12 hour dark cycle. The rats are sacrificed by decapitation before the pituitary glands are aseptically removed to tube containing Hank's Balanced Salt Solution (HBSS). The glands are further processed by:-

1. Centrifugation at 250 x g for 5 minutes;
- 10 2. Aspiration of the HBSS solution;
3. Transfer of the glands to a petri dish before mincing with a scalpel;
4. Transfer of the minced tissue to a centrifuge tube by suspending the tissue three successive times in 10 ml aliquots of HBSS containing 0.2% collagenase and 0.2% hyaluronidase;
- 15 5. Cell dispersion by gentle stirring of the tissue suspension while the tube is kept in a water bath at 37°C;
6. Aspiration 20 to 30 times using a pipette, undigested pituitary fragments being allowed to settle for 3 to 5 minutes;
7. Aspiration of the suspended cells followed by centrifugation at 1200 x g for 5 minutes;
- 20 8. Re-suspension of the cells in culture medium of DMEM containing 0.37% NaHCO₃, 10% horse serum, 2.5% foetal bovine serum, 1% non essential amino acids, 1% glutamine and 0.1% gentamycin;
9. Treatment of the undigested pituitary fragments 3 times with 30 ml aliquots of the collagenase and hyaluronidase;
- 25 10. Pooling of the cell suspensions and dilution to a concentration of 3×10^5 cells/ml;
11. Placing of 1.0ml of this suspension in each of a 24 well tray, with the cells being maintained in a humidified 5% CO₂/95% air atmosphere at 37°C for 3 to 4 days

Testing of Compounds

- 30 The test compound is dissolved in DMSO to a final concentration of 0.5% in the incubation medium.

- 62 -

1.5 hours prior to the assay, the cells are washed three times with DMEM containing 0.37% NaHCO_3 , 10% horse serum, 2.5% foetal bovine serum, 1% non essential amino acids (100X), 1% glutamine (100X), 1% penicillin/streptomycin (10,000 units of each per ml) and 25 mM HEPES at pH 7.4. Immediately prior to the assay, the cells are again washed twice in
5 this medium .


Following this, 1ml of fresh medium containing the test compound and 2nM GnRH is added to two wells. For other test compounds (where it is desired to test more than one compound), these are added to other respective duplicate wells. Incubation is then carried out at 37°C for three hours.

10 Following incubation, each well is analysed by removing the medium from the well and centrifuging the medium at 2000 x g for 15 minutes to remove any cellular material. The supernatant is removed and assayed for LH content using a double antibody radio-immuno assay. Comparison with a suitable control (no test compound) is used to determine whether the test compound reduces LH release. Compounds according to the present invention have
15 activity at a concentration from 1nM to 5 μM .

- 63 -

CLAIMS:

1. A compound of Formula (I),




Formula (I)

wherein

A represents a direct bond or optionally substituted C₁₋₅alkylene;

B is a group of Formula (II):



Formula (II);

wherein at position (a) Formula (II) is attached to the nitrogen atom and the group X is attached to R⁸;

R¹ represents hydrogen; optionally substituted C₁₋₈alkyl; or (CH₂)_b-R^a, wherein

R^a represents C₃₋₈cycloalkyl and b is zero or an integer from 1 to 6;


R² represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR³R^{3a}, optionally substituted C₁₋₈alkyl, optionally substituted C₁₋₈alkoxy or halo;

R³ and R^{3a} are independently selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;

R⁴ is hydrogen;

R⁵ is selected from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula III-a; III-b; III-c; III-d; III-e; III-f, III-g, III-h, III-i, III-j, III-k or III-l;

- 64 -



wherein **het** represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R⁶ and **R**^{6a}, are independently selected from hydrogen and optionally substituted

5 **C**₁₋₈alkyl; or **R**⁶ and **R**^{6a} together represent carbonyl;

R⁷ represents hydrogen or optionally substituted **C**₁₋₈alkyl;

or **R**⁶  **A-N-R**⁷ together form an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and **R**^{6a} represents hydrogen and optionally substituted **C**₁₋₈alkyl;

10 **X** and **R**⁸ are selected from:

(i) **X** represents N and **R**⁸ is selected from:

cyano, hydrogen, hydroxy, -**O-R**^b, -**C(O)-R**^b, -**NR**^b**R**^c -**C(O)O-R**^b, -**CONR**^b**R**^c or **NH-C(O)-R**^b, where **R**^b and **R**^c are independently selected from hydrogen and **C**₁₋₄alkyl optionally substituted with hydroxy, amino, **N-C**₁₋₄alkylamino, **N,N-di-C**₁₋₄alkylamino, **HO-C**₂₋₄alkyl-NH- or **HO-C**₂₋₄alkyl-N(**C**₁₋₄alkyl)-;

15

(ii) **X** represents CH and **R**⁸ represents **NO**₂; and

(iii) **=X-R**⁸ represents **=O**;

R¹¹ is a group of the formula: **N(R**⁹**R**¹⁰) wherein **R**⁹ represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or

20 optionally-substituted **C**₁₋₈alkyl and **R**¹⁰ represents hydrogen or optionally substituted

- 65 -


C₁₋₈alkyl; or

the structure N(R⁹R¹⁰) represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;

- 5 R¹² and R^{12a} are independently selected from hydrogen or optionally substituted C₁₋₈alkyl; or R¹² and R^{12a} together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;

R¹³ and R¹⁴ are selected from:

- 10 (i) R¹³ is selected from hydrogen; optionally substituted C₁₋₈alkyl; optionally substituted aryl; -R^d-Ar, where R^d represents C₁₋₈alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and R¹⁴ is selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;
- 15 (ii) where R⁵ represents a group of formula III-a, III-b, III-i or III-k, then the group NR¹³(-R¹⁴) represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or

- 20 (iii) where R⁵ represents structure III-e, then the group  represents an optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;

R¹⁷ is selected from: hydrogen and C₁₋₄alkyl;

or a salt, pro-drug or solvate thereof.

- 25 2. A compound according to Claim 1 wherein R⁹ represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C₁₋₈alkyl and
- 30 R¹⁰ represents hydrogen or optionally substituted C₁₋₈alkyl wherein the optional substituents on aryl, the heterocyclic ring and C₁₋₈alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, -O-R^b, C(O)NR^bR^c, -NR^bR^c, -NR^cC(O)-R^b, -C(O)NR^bR^c, -NR^cS(O₀₋₂)R^b, -S(O₀₋₂)R^b, wherein R^b and R^c are as defined in Claim 1.


- 66 -

3. A compound according to Claim 2 wherein R^9 is a C_{1-6} alkyl group substituted by pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl, benzotriazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl or 2-azetanyl, each of which is optionally substituted as defined in Claim 2.
4. A compound according to Claim 1 wherein the structure $N(R^9R^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.
5. A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from R^{15} wherein R^{15} represents the group $R^{15a}-Z-$ wherein R^{15a} is selected from optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4} alkyl and Z is selected from a direct bond, $-(CH_2)_{s1}-$, $-(CH_2)_{s1}-O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-S(O_n)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})C(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})C(O)N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OC(O)-(CH_2)_{s2}-$, $-(CH_2)_{s1}-C(O)O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})C(O)O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OC(O)N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-OS(O_n)-(CH_2)_{s2}-$, or $-(CH_2)_{s1}-S(O_n)-O-(CH_2)_{s2}-$, $-(CH_2)_{s1}-S(O)_2N(R^{18})-(CH_2)_{s2}-$, $-(CH_2)_{s1}-N(R^{18})S(O)_2-(CH_2)_{s2}-$; wherein the $-(CH_2)_{s1}-$ and $-(CH_2)_{s2}-$ groups are independently optionally substituted by hydroxy or C_{1-4} alkyl and $s1$ and $s2$ are independently an integer from 0 to 2, wherein $s1+s2$ is less than or equal to 2 and R^{18} is selected from hydrogen or C_{1-4} alkyl; wherein the optional substituents on aryl, a heterocyclic ring or C_{1-4} alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^g$, $-C(O)-R^g$, $-C(O)NR^gR^h$, $--NR^gR^h$, $-NR^hC(O)-R^g$, $-C(O)NR^gR^h$, $-NR^hS(O_{0-2})R^g$, $-S(O_{0-2})R^g$, wherein R^g

- 67 -

and R^g are independently selected from: heterocyclyl, hydrogen and C_{1-4} alkyl optionally substituted with hydroxy, amino, N - C_{1-4} alkylamino, N,N -di- C_{1-4} alkylamino, HO - C_{2-4} alkyl-NH- or HO - C_{2-4} alkyl- $N(C_{1-4}$ alkyl)-.

- 5 6. A compound according to Claim 5, wherein Z is selected from a direct bond or carbonyl.
7. A compound according to any one of the preceding claims wherein R^5 is selected from a group of formula III-a, III-g, III-h, III-i or III-j:



10

8. A compound according to any one of the preceding claims wherein:
- (a) X represents N and R^8 represents cyano or $-C(O)O-R^b$; wherein R^b is as defined in Claim 1, or
- 15 (b) X represents N and R^8 represents hydrogen.
9. A compound according to any one of the preceding claims wherein R^2 is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR^eR^f , optionally substituted C_{1-8} alkyl, optionally substituted C_{1-8} alkoxy or halo wherein R^e and R^f are independently selected from
- 20 hydrogen, C_{1-6} alkyl or aryl.
10. A compound according to any one of the preceding claims wherein R^1 is hydrogen.

- 68 -


11. A compound selected from:
 - 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1*S*-methyl-2-(*N'*-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximida
mido) ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
 - 5 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[2-(*N'*-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximidamido)
ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
 - 2-(2-pyrrolidin-1-yl-1,1-dimethyl-2-oxoethyl)-
4-[1*S*-methyl-2-(*N'*-isopropoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-ylcarboximida
10 mido) ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
 - 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1*S*-methyl-2-(*N'*-isopropoxycarbonyl-4-tetrahydropyran-4-yl-
piperidin-1-ylcarboximidamido)ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-
15 *b*]pyrrole;
 - 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1*S*-methyl-2-(3-pyrid-4-yl-pyrrolidin-1-ylcarbonyl)ethyl]-5-(3,5-
dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;
 - 2-(1,1-dimethyl-2-oxo-2-azabicyclo[2.2.1]heptan-7-ylethyl)-
4-[1*S*-methyl-2-(*N'*-ethoxycarbonyl-3-pyrid-4-yl-pyrrolidin-1-yl
20 carboximidamido) ethyl]-5-(3,5-dimethylphenyl)--6*H*-thieno[2,3-*b*]pyrrole;

or a salt, pro-drug or solvate thereof.
12. A compound, or salt, pro-drug or solvate thereof, according to any one of Claims
1 to 11 for use as a medicament.
- 25 13. A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate
thereof, according to any one of Claims 1 to 11 and a pharmaceutically acceptable
diluent or carrier.
- 30 14. Use of a compound, or salt, pro-drug or solvate thereof, according to any one of Claims
1 to 11, in the manufacture of a medicament for administration to a patient, for
therapeutically treating and/or preventing a sex hormone related condition in the patient.

- 69 -


15. A process of producing a compound, or salt, pro-drug or solvate thereof, according to any one of Claims 1 to 11, wherein the process comprises a reaction step selected from any one of steps (a) to (f):-

(a) Reaction of a compound of formula **XXXII** as follows




5

(b) Cleavage of the cyano group of a compound of formula **XXXIII** in the presence of acid to produce a compound of formula **XXXIV**




10

(c) Reaction of a compound of formula **XXXV** as follows




- 70 -


(d) Reaction of a compound of formula XXXVII as follows



(e) Reaction of a compound of formula XXXIX as follows



(f) to form a compound wherein X is nitrogen and Reaction of a compound of formula XXXXI as follows



and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/03603

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D495/04 A61K31/40 A61P35/00 //(C07D495/04,333:00,
209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 53185 A (MERCK & CO INC ;WALSH THOMAS F (US); UJJAINWALLA FEROZE (US)) 14 September 2000 (2000-09-14) cited in the application claims 1,4	1-15
A	WO 99 41251 A (GOULET MARK T ;MERCK & CO INC (US); WALSH THOMAS F (US); FISHER MI) 19 August 1999 (1999-08-19) cited in the application claims 1,4	1-15
A	US 6 025 366 A (GOULET MARK T ET AL) 15 February 2000 (2000-02-15) claims 1,4	1-15
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

14 November 2003

Date of mailing of the international search report

25/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bakboord, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 03/03603

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 70227 A (GOULET MARK T ;DEVITA ROBERT J (US); MERCK & CO INC (US); PARIKH M) 27 September 2001 (2001-09-27) claims 1,6 ----	1-15
A	US 6 340 686 B1 (CHOH NOBUO ET AL) 22 January 2002 (2002-01-22) claims 1,15 ----	1-15
P,A	WO 02 092565 A (WARDLEWORTH JAMES MICHAEL ;ASTRAZENECA UK LTD (GB); DOSSETTER ALEX) 21 November 2002 (2002-11-21) cited in the application claims 1,11 -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/03603

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0053185	A	14-09-2000	AU 3514200 A CA 2367130 A1 EP 1171135 A1 JP 2002538208 A WO 0053185 A1 US 6288078 B1	28-09-2000 14-09-2000 16-01-2002 12-11-2002 14-09-2000 11-09-2001
WO 9941251	A	19-08-1999	AU 2597299 A CA 2317451 A1 EP 1068195 A1 JP 2002503660 T WO 9941251 A1 US 6159975 A	30-08-1999 19-08-1999 17-01-2001 05-02-2002 19-08-1999 12-12-2000
US 6025366	A	15-02-2000	AU 3117899 A CA 2325995 A1 EP 1067929 A1 JP 2002510628 T WO 9951231 A1	25-10-1999 14-10-1999 17-01-2001 09-04-2002 14-10-1999
WO 0170227	A	27-09-2001	AU 4738101 A WO 0170227 A1	03-10-2001 27-09-2001
US 6340686	B1	22-01-2002	AU 764019 B2 AU 3326200 A BR 0009297 A CA 2368108 A1 CN 1349536 T CZ 20013419 A3 EP 1163244 A1 HU 0200550 A2 WO 0056739 A1 JP 3240293 B2 JP 2001278884 A JP 2001278885 A NO 20014603 A NZ 514737 A PL 351202 A1 SK 13552001 A3 US 6297379 B1 ZA 200108165 A	07-08-2003 09-10-2000 18-12-2001 28-09-2000 15-05-2002 13-02-2002 19-12-2001 29-06-2002 28-09-2000 17-12-2001 10-10-2001 10-10-2001 26-11-2001 31-10-2003 24-03-2003 05-03-2002 02-10-2001 04-10-2002
WO 02092565	A	21-11-2002	WO 02092565 A2	21-11-2002